Clinical trial NCT05482698
Conditions: Chronic Kidney Disease-associated Pruritus
Sponsor: MC2 Therapeutics
Start date: 2022-07-01; Completion date: 2024-02-02
Enrollment: 111 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to access the efficacy and safety of MC2-25 cream and MC2-25 vehicle for treatment of chronic kidney disease associated pruritus (CKD)-aP).

Detailed description:
In this trial, subjects who fulfil all inclusion and exclusion criteria are enrolled.

Eligible subjects will be randomised in a 2:1 ratio to MC2-25 cream or MC2-25 vehicle, respectively.

The subjects will apply the assigned investigational medicinal product (IMP) twice daily for 12 weeks.

Arms: arm 1: MC2-25 cream Twice daily applications for 12 weeks arm 2: MC2-25 vehicle Twice daily applications for 12 weeks
Interventions: intervention 1: MC2-25 cream intervention 2: MC2-25 vehicle
Intervention descriptions: intervention 1: Topical application intervention 2: Topical application

Protocol documents:
Prot_000.pdf: 
Protocol No. MC2-25-C1 
Vers. 3.0 EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
 
 
 
Clinical Trial Protocol 
 
Trial Title: 
A Parallel-group (2-Arm), Randomized, Double-blind, 
12-week Trial to Evaluate the Efficacy and Safety of 
MC2-25 Cream and MC2-25 Vehicle in Subjects with 
Chronic Kidney Disease-associated Pruritus (CKD-aP) 
 
Investigational product: 
MC2-25 cream  
 
Active Comparator: 
Not applicable 
 
Protocol No: 
MC2-25-C1 
 
Short title: 
ITCHINESS 
 
EUDRACT: 
2021-006971-40 
 
EUCT: 
2022-500044-38-01 
 
Development phase: 
2 
 
Document status: 
Final 
 
Document version: 
Version 3.0_EU 
 
Document date: 
30-Nov-2022  
 
Sponsor: 
 
 
MC2 Therapeutics Ltd 
1A Guilford Business Park 
Guilford GU2 8XG 
United Kingdom 
 
EU representative: 
MC2 Therapeutics A/S 
c/o Agern Alle 24-26 
2970 Hørsholm 
Denmark 
 
Property of MC2 Therapeutics 
Confidential The confidential information provided in this document is for use by parties directly 
involved in this investigation. This document is delivered in confidence that such information will not 
be copied or made available to any third party without the written consent of MC2 Therapeutics.   


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 2 - 
CLINICAL TRIAL PROTOCOL APPROVAL 
Product: MC2-25 cream 
Protocol number: MC2-25-C1 
Protocol title: A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to 
Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects with 
Chronic Kidney Disease-associated Pruritus (CKD-aP) 
Short title: The MC2-25 cream in subjects wITh CHronic KIdNEy disease-aSsociated 
prurituS (ITCHINESS) trial 
The following persons have approved this clinical trial protocol, as reflected in separate 
documents adjoined to this document:  
Maj Dinesen, Director of Clinical Development, MC2 Therapeutics  
Birgitte Vestbjerg, Senior Advisor Clinical Operations, MC2 Therapeutics 
Frank Freischläger, Senior Advisor Biostatistics, Estimondo 
Kieran McCafferty, International Coordinating Investigator, Consultant Nephrologist Barts 
Health NHS Trust 
 
 
 


-+/++(+

	
!-.+1




(%*%(-%(-+/++(


$!-,!0/%.




	



 

-!)
 

	
-((!(#-+0,
-)* +)%4! +0(!(%* 	
2!!'-%(/+
1(0/!/$!""%3* "!/3+"

-!)* 

!$%(!%*0&!/.2%/$
$-+*%% *!3%.!.!..+%/! -0-%/0.
$!.%#*/0-!+"/$!*/!-*/%+*(++- %*/%*#*1!./%#/+-!(+2+*./%/0/!.$%.$!-
,,-+1(+"/$%.,-+/++(* ,-+1% !./$!*!!..-3..0-*!./$//$%./-%(2%((!
+* 0/! +- %*#/+((./%,0(/%+*.(%*%(*  )%*%./-/%1!. !/%(! %*/$!
,-+/++($!/-%(2%((*+/!%*%/%/! 2%/$+0//$!,,-+1(+"*,,-+,-%/!*./%/0/%+*(
!1%!2+- +-/$%.!1%!2+))%//!!* /$!,,-+1("-+)/$!,,-+,-%/!$!(/$
0/$+-%/3


%!-*""!-/3
*/!-*/%+*(++- %*/%*#*1!./%#/+-5.,-%*/! *)!




*/!-*/%+*(++- %*/%*#*1!./%#/+-5..%#*/0-!

/!


30/Nov/2022


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 4 - 
TABLE OF CONTENTS 
TABLE OF CONTENTS ..............................................................................................................4 
LIST OF TABLES .........................................................................................................................7 
LIST OF FIGURES .......................................................................................................................7 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ...............................................8 
1.0 
SYNOPSIS ..........................................................................................................................10 
2.0 
INTRODUCTION ..............................................................................................................13 
2.1 
Background ..............................................................................................................13 
2.1.1 
Chronic kidney disease-associated pruritus .................................................13 
2.1.2 
MC-25 cream ................................................................................................14 
2.2 
Rationale of the trial .................................................................................................16 
2.3 
Benefit-risk assessment ............................................................................................17 
3.0 
TRIAL OBJECTIVES AND PURPOSE ..........................................................................22 
4.0 
TRIAL DESIGN .................................................................................................................22 
4.1 
Overall trial design ...................................................................................................22 
4.2 
Trial endpoints ..........................................................................................................23 
5.0 
SELECTION OF TRIAL POPULATION .......................................................................25 
5.1 
Subject population ....................................................................................................25 
5.2 
Inclusion criteria .......................................................................................................25 
5.3 
Exclusion criteria ......................................................................................................27 
5.4 
Withdrawal from trial and discontinuation of treatment ..........................................29 
5.5 
Replacement policy ..................................................................................................30 
6.0 
TRIAL TREATMENTS ....................................................................................................30 
6.1 
Investigational medicinal product ............................................................................30 
6.2 
Vehicle product ........................................................................................................30 
6.3 
Dosing regimen ........................................................................................................30 
6.4 
Dose modification ....................................................................................................30 
6.5 
Packaging, labelling and storage ..............................................................................30 
6.6 
Assignment to treatment ...........................................................................................31 
6.6.1 
Randomisation ..............................................................................................31 
6.6.2 
Blinding ........................................................................................................31 
6.7 
Prior, concomitant, and prohibited therapies ...........................................................31 
6.7.1 
Prohibited therapies prior to baseline ...........................................................32 
6.7.2 
Prohibited therapies from baseline to the end of the treatment period .........32 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 5 - 
6.8 
Therapies not listed are allowed. Treatment compliance and drug 
accountability ...........................................................................................................33 
7.0 
VISIT SCHEDULE AND ASSESSMENTS .....................................................................34 
7.1 
Visit schedule ...........................................................................................................34 
7.2 
Demographics and medical history ..........................................................................38 
7.3 
Prior and concomitant therapies ...............................................................................38 
7.4 
Physical examination ................................................................................................38 
7.5 
Vital signs .................................................................................................................38 
7.6 
Electrocardiogram (ECG).........................................................................................39 
7.7 
Pregnancy test ..........................................................................................................39 
7.8 
Laboratory assessments ............................................................................................39 
7.8.1 
Haematology and biochemistry ....................................................................40 
7.9 
Patient-reported outcome (PRO) assessments ..........................................................40 
7.9.1 
Worst itch numeric rating score (WI-NRS) .................................................40 
7.9.2 
Sleeploss due to itch numeric rating score (SI-NRS) ...................................40 
7.9.3 
Skin dryness numeric rating score (SD-NRS) ..............................................40 
7.9.4 
Subject’s global impression of change (SGIC) ............................................41 
7.9.5 
Subject’s rating of importance of improvement ...........................................41 
7.9.6 
Health-related quality of life (HRQoL) ........................................................41 
7.9.6.1 
Skindex-10 .......................................................................................42 
7.9.6.2 
5D-Itch ............................................................................................42 
7.9.6.3 
EQ-5D-5L ........................................................................................42 
7.9.7 
Subject’s indication of CKD-aP treatment area size ....................................43 
7.10 
Clinician-reported outcome (ClinRO) assessments .................................................44 
7.10.1 
Identification of CKD-aP target area............................................................44 
7.10.2 
Clinician’s global assessment (CGA) of skin appearance ...........................45 
7.10.3 
Clinician’s targeted assessment (CTA) of skin appearance .........................46 
7.10.4 
Imaging of CKD-aP .....................................................................................47 
7.11 
Biomarker assessments of CKD-aP .........................................................................47 
7.11.1 
Skin biopsies ................................................................................................48 
7.11.2 
Skin tape strips .............................................................................................48 
7.12 
Adverse events .........................................................................................................49 
7.12.1 
Adverse events assessments .........................................................................49 
7.12.2 
Reporting of adverse events .........................................................................49 
7.12.3 
Severity of adverse events ............................................................................50 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 6 - 
7.12.4 
Relationship of adverse events to trial treatment .........................................50 
7.12.5 
Outcome of adverse event ............................................................................51 
7.12.6 
Unexpected serious adverse events ..............................................................51 
7.12.7 
Trial medication overdose ............................................................................51 
7.12.8 
Pregnancy .....................................................................................................51 
7.12.9 
Serious adverse event ...................................................................................51 
7.12.10 Reporting of serious adverse events and pregnancies ..................................52 
7.12.10.1 Contact person(s) and number(s)....................................................52 
7.12.10.2 Reporting procedures ......................................................................53 
7.13 
COVID-19 Considerations .......................................................................................53 
8.0 
STATISTICAL AND ANALYTICAL PLANS AND DETERMINATION OF 
SAMPLE SIZE ...................................................................................................................54 
8.1 
General considerations for data analysis ..................................................................54 
8.2 
Sample size and power considerations .....................................................................54 
8.3 
Analysis populations ................................................................................................54 
8.4 
Background and demographic characteristics ..........................................................55 
8.5 
Trial medication/exposure ........................................................................................55 
8.6 
Prior and concomitant therapies ...............................................................................55 
8.7 
Analysis of safety .....................................................................................................55 
8.7.1 
Adverse events .............................................................................................55 
8.8 
Analysis of efficacy ..................................................................................................56 
8.8.1 
Primary endpoint ..........................................................................................56 
8.8.2 
Secondary endpoints ....................................................................................57 
9.0 
CHANGES IN THE PLANNED TRIAL .........................................................................57 
9.1 
Protocol amendments ...............................................................................................57 
9.2 
Completion, Termination or suspension of the trial .................................................57 
10.0 DATA HANDLING AND RECORD KEEPING ............................................................58 
10.1 
Recording of data .....................................................................................................58 
10.1.1 
Source documents ........................................................................................59 
10.1.2 
Case report forms .........................................................................................59 
10.2 
Retention of documents ............................................................................................60 
11.0 QUALITY CONTROL AND QUALITY ASSURANCE ...............................................60 
11.1 
Direct Access to source documents ..........................................................................60 
11.2 
Monitoring procedures .............................................................................................60 
11.3 
Audit and inspection .................................................................................................60 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 7 - 
12.0 ETHICS ...............................................................................................................................61 
12.1 
Ethical conduct of the trial .......................................................................................61 
12.2 
Institutional review board (IRB) or independent ethics committee (IEC) ...............61 
12.3 
Subject information and consent ..............................................................................61 
12.4 
Disclosure and confidentiality ..................................................................................61 
12.4.1 
Confidentiality of trial documentation .........................................................61 
12.4.2 
Privacy of individual health information .....................................................61 
12.5 
Subject involvement in the design of the clinical trial .............................................62 
13.0 EMERGENCY PROCEDURES .......................................................................................62 
13.1 
Emergency unblinding .............................................................................................62 
14.0 INSURANCE ......................................................................................................................62 
15.0 PUBLICATION POLICY .................................................................................................62 
16.0 REFERENCES ...................................................................................................................62 
17.0 APPENDICES ....................................................................................................................66 
17.1 
Appendix 1 Contact list of MC2 and protocol authors ............................................66 
17.2 
Appendix 2 Vendor overview ..................................................................................67 
 
 
LIST OF TABLES 
 
Table 1: 
Summary of Risks and Mitigation Strategies .............................................................19 
Table 2: 
Prohibited Therapies Prior to Baseline .......................................................................32 
Table 3: 
Visit Schedule .............................................................................................................35 
 
LIST OF FIGURES 
Figure 1: 
MC2-25-C1 Clinical Trial Design ..............................................................................22 
 
 
 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 8 - 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
Abbreviation 
Definition 
AD 
Atopic dermatitis 
ADR 
Adverse drug reaction 
AE 
Adverse event 
BSA 
Body surface area 
CGA 
Clinician’s Global Assessment 
CTA 
Clinician’s Targeted Assessment 
CKD 
Chronic kidney disease 
CKD-aP 
Chronic kidney disease-associated pruritus 
ClinRO 
Clinician-reported outcome 
COVID-19 
Coronavirus disease 2019 
CRO 
Contract research organization 
DOPPS 
Dialysis Outcomes and Practice Patterns Study 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate 
EoT 
End of treatment 
EQ-5D-5L 
EuroQoL 5 Dimensions, 5 levels 
ESRD 
End-stage renal disease 
EU 
European Union 
FAS 
Full analysis set 
FTU 
Fingertip unit 
GCP 
Good Clinical Practice 
HD 
Haemodialysis 
HDF 
Haemodiafiltration 
HRQoL 
Health-related quality of life 
IB 
Investigator’s Brochure 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IMP 
Investigational medicinal product 
IRB 
Institutional Review Board 
IV 
Intravenous(ly) 
IWR 
Interactive web response 
LOCF 
Last observation carried forward 
MFAS 
Modified full analysis set 
NMF 
Natural moisturizing factor 
PPS 
Per-protocol set 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 9 - 
Abbreviation 
Definition 
PRO 
Patient-reported outcome 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SAS 
Safety analysis set 
SD 
Skin Dryness 
SD-NRS 
Skin Dryness Numeric Rating Score 
SGIC 
Subject’s Global Impression of Change 
SI 
Sleeploss due to Itch 
SI-NRS 
Sleeploss due to Itch Numeric Rating Score 
SoA 
Schedule of assessments 
SmPC 
Summary of Product Characteristics 
SS 
Screened set 
SUSAR 
Suspected unexpected serious adverse reaction 
TEAE 
Treatment-emergent adverse event 
TOM 
Technical-operational measures 
USPI 
United States prescribing information 
UV-B 
Ultraviolet B 
VAS 
Visual analogue scale 
WI 
Worst Itch 
WI-NRS 
Worst Itch Numeric Rating Score 
w/w 
Weight by weight 
 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 10 - 
1.0 
SYNOPSIS 
Trial Title: 
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to 
Evaluate the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in 
Subjects with Chronic Kidney Disease-associated Pruritus (CKD-aP) 
Protocol Number: 
MC2-25-C1 
Sponsor: 
MC2 Therapeutics Ltd 
Development Phase: 
2 
Trial Objectives: 
The primary objective is to explore the clinical efficacy of MC2-25 cream 
compared to MC2-25 vehicle in adults with chronic kidney disease-associated 
pruritus (CKD-aP). 
The secondary objectives are to explore the safety of MC2-25 cream compared 
to MC2-25 vehicle in adults with CKD-aP and to explore the subclinical 
effects of MC2-25 cream in adults with CKD-aP. 
Trial Design: 
This is a multicentre, phase 2, randomized, double-blind, 2-arm, parallel-group 
and vehicle-controlled trial in subjects with CKD-aP. Eligible subjects will be 
randomised in a 2:1 ratio to MC2-25 cream or MC2-25 vehicle, respectively. 
Subjects will apply the assigned investigational medicinal product (IMP) twice 
daily for 12 weeks. 
Subjects will be seen at the trial sites at Screening, Baseline, Week 1, Week 4, 
Week 8, and Week 12 (end of treatment, EoT). Subjects who have ongoing 
serious adverse events (SAEs) or related adverse events (AEs) at Week 12 will 
have a follow-up visit at Week 14 or (in case of early treatment 
discontinuation) 14 days after the EoT visit, whichever comes first. 
Additionally, phone contacts are planned at Week 2, Week 6, and Week 10. 
Planned Sample Size: 
Approximately 108 subjects will be randomised in the trial in a 2:1 ratio of 
MC2-25 cream to MC2-25 vehicle, including an assumption of 10% dropouts. 
Trial Population: 
Males or non-pregnant females at least 18 years of age who have chronic 
(>3 months) kidney disease (CKD) stages G3-G5 (estimated glomerular 
filtration rate (eGFR) < 60 mL/min/1.73 m2) and at least moderate CKD-aP, 
defined as WI-NRS ≥4 (i.e., the average of all and at least 4 non-missing scores 
reported by the subject in the diary for 7 days prior to and including the 
Baseline day, 8 days in total). Both subjects on dialysis (haemodialysis or 
haemodiafiltration) and not on dialysis will be enrolled. 
Investigational Medicinal 
Product: 
MC2-25 cream for topical application (MC2-25 cream) 
Vehicle: 
MC2-25 vehicle for topical application (MC2-25 vehicle) 
Primary Endpoint: 
• 
Mean change in weekly mean Worst Itch Numeric Rating Score 
(WI-NRS) recorded in the subject’s diary from Baseline to Week 12 for 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 11 - 
MC2-25 cream compared to MC2-25 vehicle. (Weekly mean WI-NRS is 
calculated as the average of WI-NRS values recorded in the subject’s diary 
7 days prior to and including the visits.) 
Secondary Endpoints: 
• 
Percentage of subjects obtaining a ≥4-point improvement in weekly mean 
WI-NRS recorded in the subject’s diary from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle. 
• 
Percentage of subjects obtaining a ≥3-point improvement in weekly mean 
WI-NRS recorded in the subject’s diary from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle.  
• 
Percentage of subjects obtaining a complete response in weekly mean 
WI-NRS recorded in the subject’s diary from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle. (Complete response is 
defined as scores equal to 0 or 1 in ≥80% of the non-missing WI-NRS 
values recorded in the subject’s diary 7 days prior to and including the 
visits.) 
Other Endpoints: 
Additional endpoints are included in the Clinical Trial Protocol. 
Safety Endpoints: 
• 
Frequencies of treatment-emergent adverse events (TEAEs), SAEs, 
adverse drug reactions (ADRs), AEs leading to treatment discontinuation 
or trial withdrawal, and deaths during the trial for MC2-25 cream 
compared to MC2-25 vehicle. 
• 
Changes in mean safety assessments: vital signs (heart rate, systolic blood 
pressure, diastolic blood pressure, temperature), and blood samples 
(biochemistry, haematology) from Baseline to Week 12 for MC2-25 cream 
compared to MC2-25 vehicle. 
• 
Frequency of clinically significant abnormal physical examinations and 
ECGs from Baseline to Week 12 for MC2-25 cream compared to MC2-25 
vehicle. 
• 
Percentage of subjects who missed 1 or more dialysis visits during the 
Double-blind Treatment Period. 
Statistical Methods: 
Efficacy analysis: The primary endpoint of the trial, mean change in weekly 
mean WI-NRS recorded in the subject’s diary from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle, will be analysed by a mixed 
model of repeated measures with Baseline weekly mean WI-NRS as covariate 
and treatment, CKD stage stratum at baseline, systemic CKD-aP treatment 
status at baseline and visit as fixed factors with a two-sided α = 0.05. 
Treatment groups are compared for the superiority of MC2-25 cream over 
MC2-25 vehicle after 12 weeks of treatment. Due to the Phase II type of the 
trial, no alpha adjustment will be carried out for secondary endpoints.  
Safety Analysis: Safety data will be summarized using descriptive statistics (n, 
mean, standard deviation, median, minimum, and maximum) for continuous 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 12 - 
variables and frequency distributions (counts and percentages) for categorical 
variables. 
Trial Sites: 
Approximately 26 sites will be opened in United Kingdom (UK) and (EU).  
Planned Dates of Trial: 
FPFV: H1 2022 
LPLV: H2 2023 
 
 
 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 13 - 
2.0 
INTRODUCTION 
2.1 
Background 
2.1.1 
Chronic kidney disease-associated pruritus 
The global prevalence of Chronic Kidney Disease (CKD) is around 9·1% and the prevalence of 
CKD increases with age (Collaboration, Chronic Kidney Disease, 2020; Hill 2016). Patients with 
chronic kidney disease (CKD) are afflicted by severe pruritus, referred to as CKD-associated 
pruritus (CKD-aP) or uremic pruritus. Pruritus has most thoroughly been investigated in patients 
with end-stage renal disease (ESRD) on haemodialysis. The pruritus often presents with 
fluctuating intensity, often worse during nighttime than daytime, resulting in sleep disturbances. 
Most patients report itching over large, discontinuous, non-dermatomal regions of skin, often 
with bilateral symmetry (Mathur 2010).  
The significant impact of itch on ESRD patients’ quality of life is generally accepted. According 
to the Dialysis Outcomes and Practice Patterns Study (DOPPS), which included 
23,264 haemodialysis patients from 21 countries, the proportion of CKD patients on 
haemodialysis who are at least moderately bothered by self-reported pruritus is 37%, and 7% are 
extremely bothered. The trial also found that pruritus was associated with higher risk for 
hospitalizations and death, higher rates of withdrawal from dialysis and missing scheduled 
dialysis treatments, and lower rates of employment. Additionally, severe pruritus was strongly 
associated with self-reported depression, self-reported restless sleep, and progressively poorer 
self-reported mental and physical Health Related-Quality of Life (Sukul 2021). In a previous 
DOPPS trial the increased mortality in patients with severe itch was no longer significant after 
adjusting for sleep quality measures (Pisoni 2006).  
Recent studies indicate that moderate to severe/extreme patient-reported pruritus is common 
regardless of whether or not patients are on haemodialysis and that more severe pruritus is 
associated with negative effects on several patient-reported outcomes (PROs). A major study 
with more than 5,600 CKD-aP patients from the United States, Brazil, and France found that the 
prevalence of moderate to extreme pruritus was 24% and there was only weak correlation 
between the degree of kidney failure and the intensity of pruritus. The same trial also indicated 
older age was associated with higher prevalence of moderate-to-extreme pruritus (Sukul 2019).  
The pathogenic basis of pruritus in patients with renal failure is unknown. Numerous suggestions 
for the aetiology of the pruritus (e.g., hyperparathyroidism, allergic sensitization, neuropathy, 
various abnormal laboratory values) have been evaluated without positive results (Martin 2020). 
One hypothesis is that the symptoms typical of chronic kidney failure can be explained by 
excessive protein carbamylation, referring to the binding of isocyanic acid on free amino acids 
and proteins. Urea that is elevated in CKD is via a slow equilibrium a source of formation of 
isocyanic acid (Jaisson 2018, Kraus 1998).  


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 14 - 
It is known that the metabolism of many amino acids and proteins is altered in advanced renal 
failure to the extent that uremic patients acquire symptoms of malnutrition (Kopple 1978). One 
of the key reasons for this may be the extensive carbamylation of serum essential amino acids 
that is seen in uremic patients. The level of carbamylation of such amino acids can be extensive 
with up to 10 times molar excess of carbamylated amino acids compared to non-carbamylated 
amino acids (Kraus 1998). The carbamylated amino group cannot participate in the protein 
synthesis, which requires an un-derivatized amino acid, and it has been demonstrated that 
carbamylated amino acids inhibit protein synthesis (Kraus 2001).  
The concentration of urea is higher in sweat than in other body compartments (Baker 2020). 
Furthermore, the evaporation of water from the skin will lead to concentration of urea on the 
surface of the skin. The high level of urea on the skin surface creates a concentration gradient of 
urea through the uppermost layers of the skin resulting in extensive carbamylation of amino 
acids and proteins in the epidermis. Free amino acids are readily carbamylated, which means that 
the levels of un-derivatized amino acids are reduced in the stratum corneum skin in patients with 
CKD. Since skin amino acids are important humectants, this may be the reason that uremic skin 
is most often dry, as carbamylated amino acids presumably are not good humectants. Isocyanate 
is known to be neurotoxic in animals (Kimani 2014) and in humans (Adamolekun 2011). In 
patients with CKD, intra-epidermal fibres often demonstrate nerve sprouting (Johansson 1989), 
probably because of nerve damage. Although not proven, carbamylation in the skin may affect 
afferent small nerve fibres resulting in the sensation of itch. Scratch marks in uremic patients are 
often lined with epidermal haemorrhagic bleedings – a result of mechanical ruptures of small 
blood vessels where supporting connective tissues (collagen and elastin) have lost their elastic 
properties due to carbamylation (Gorisse 2016, Jaisson 2006). 
A number of treatment strategies exist for CKD-aP (e.g., optimization of dialysis parameters, 
topical emollients and analgesics, antihistamines, GABA analogues (gabapentin and pregabalin), 
kappa opioid agonists (nalfurafine, diefelikefalin), ultraviolet light B (UV-B) phototherapy) but 
apart from GABA analogues and kappa opioid receptor agonists the evidence supporting their 
efficacy is limited (Hercz 2020, Rayner 2017, Shirazian 2017). Furthermore, except for 
nalfurafine (Remitech®), which is only marketed in Japan (Nalfurafine Report 2008), and 
difelikefalin (Korsuva®), which at the present time is only approved in the US and carries a risk 
of gastrointestinal and nervous system side effects (Korsuva USPI 2021), there are currently no 
approved and marketed drugs for treatment of CKD-aP. Therefore, there is a high unmet need for 
a safe and efficient treatment option.  
2.1.2 
MC-25 cream  
MC2-25 cream consists of the dipeptide L-Alanyl-L-Glutamine (Ala-Gln) as the active drug 
substance in a cream base. Ala-Gln is intended to act as a scavenger for isocyanate, thereby 
preventing protein carbamylation. A series of in vitro assays demonstrated that Ala-Gln was 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 15 - 
among the most efficient amino acid and peptide compounds in terms of preventing protein 
carbamylation, that Ala-Gln achieved ~65% inhibition of protein carbamylation compared with 
histidine, for example, that only achieved ~39% inhibition, and that Ala-Gln showed a dose-
dependent inhibition of protein carbamylation reaching 89% inhibition at a 3% Ala-Gln strength. 
Further details are provided in the Investigator’s Brochure (IB) Section 4.2.1, Primary 
pharmacology.  
A pilot clinical test (n=2) indicated that application of a urea cream to healthy human skin (to 
mimic urea and isocyanate levels in CKD-aP skin) leads to a decrease in amino acids and an 
increase in carbamylated proteins in the skin. This was supported by a subsequent pilot clinical 
trial in CKD-aP patients (n=3) and an age-matched control group (n=3) that indicated that the 
total level of natural moisturizing factors (NMFs) (amino acids are an important source of 
NMFs) is reduced in CKD-aP compared to healthy human skin (see IB Section 4.2, Nonclinical 
pharmacology for further details).  
An in vitro assay indicated that homogenized healthy human skin contains significant levels of 
both Ala-Gln and its metabolites. It is likely that in CKD-aP skin endogenous levels of Ala-Gln 
and its metabolites are considerably lower due to carbamylation. In a skin penetration study on 
whole fresh human abdominal skin samples, only ~ 4% of the applied Ala-Gln dose was 
recovered in the skin and <1% of the applied dose reached the receptor fluid (a surrogate for 
systemic exposure) (see IB Section 4.3.1, Absorption and pharmacokinetics for further details). 
Due to itching and dryness, CKD-aP skin may theoretically resemble atopic dermatitis (AD) skin 
with resulting higher skin permeation than across healthy skin. An in vitro study (n=35) 
indicated that permeation of theophylline was 2 to 2.5-fold higher across AD epidermis 
compared to healthy control skin (Yoshiike 1993). In man the plasma half-life of Ala-Gln is 
<5 min (varies between 2.4 and 3.8 min; 4.2 min in terminal renal insufficiency) 
(Dipeptiven SmPC 2015). There are no available data on the distribution, excretion, and drug-
drug interaction properties of Ala-Gln. However, based on the expected low systemic availability 
of Ala-Gln after application of MC2-25 cream (<1%) and the short half-life in plasma (<5 min), 
the contribution of topically applied MC2-25 cream to the endogenous amino acid homeostasis 
or to drug-drug interactions is expected to be negligible (see IB Section 4.3, Pharmacokinetics 
and product metabolism in animals for further details). 
MC2-25 cream was found to be safe and well tolerated when applied topically, twice daily for 
2 weeks in minipigs. Systemic toxicity studies have not been performed with MC2-25 cream. 
However, the systemic toxicity of Ala-Gln was explored (up to 13 weeks in rats and dogs) as part 
of the development of Dipeptiven®, which is a product for intravenous (IV) infusion with 
Ala-Gln as the active ingredient. As described in the following section, safety margins can be 
inferred from the maximum clinical dose and the benign safety profile provided in the 
Dipeptiven® SmPC 2015.  


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 16 - 
Dipeptiven®, a product containing Ala-Gln that was approved in 1995 in the EU for parenteral or 
enteral administration in association with hypercatabolic conditions, has a benign safety profile. 
According to the European SmPC, Dipeptiven® can be administered to adult patients up to 
maximum daily doses equivalent to 0.5 g per kg body weight for 3 weeks (Dipeptiven® SmPC 
2015). In addition, no adverse safety signals were observed in a phase 2 randomized controlled 
trial evaluating biomarkers of peritoneal health that included 50 patients who were randomized 
to Ala-Gln (8 mM) or placebo added to their peritoneal dialysis fluid for 8 weeks (Vychytil 
2018). Therefore, as systemic administration of Ala-Gln in humans appears safe, dermally 
applied Ala-Gln is also considered to be safe in humans although the safety of MC2-25 cream 
(dermally applied Ala-Gln) in humans has not been investigated yet. 
2.2 
Rationale of the trial 
The trial uses a randomized, double-blind, vehicle-controlled design to minimize the potential for 
bias. By using blinding and randomization and including a group that receives vehicle, the trial 
design controls for potential influences on the results other than those arising from the 
pharmacologic action of MC-25 cream (Ala-Gln). 
Based on reported plasma and skin urea concentrations, and literature regarding urea chemistry 
and biology, it can be estimated that the amount of isocyanate formed and present in the skin of 
dialysis patients can be as high as ~10 nmol/cm2 due to elevated levels of plasma urea (see IB 
Section 2, Introduction for further details). As a rough estimate, to effectively scavenge this 
amount of isocyanate at any time, the amount of nucleophile (Ala-Gln) added via a cream would 
have to be at least in the same range. One fingertip unit (FTU) of MC2-25 cream weighs 
approximately 500 mg (data on file). This is in line with findings for other topical formulations 
and it is generally accepted that 1 FTU can cover approximately two handprints (Finlay 1989, 
Finlay 2012), which correspond to 2% of the body surface area (BSA) or an average of 358 cm2 
in adult men and women (Sacco 2010, Thomas 2007). The amount of scavenger needed in one 
gram of cream can then be calculated by multiplying 10 nmol Ala-Gln/cm2 skin by 716 cm2 
skin/g cream, which adds up to 7.2 x 10-6 mol Ala-Gln/g cream. With a molecular weight of 
217.22 g/mol this corresponds to a cream strength of 0.0016 g Ala-Gln/g cream, i.e., a ~ 0.16% 
(w/w) formulation. However, several factors may affect the estimation, including extent of 
absorption/penetration of Ala-Gln, reaction efficiency between Ala-Gln and isocyanate, stability 
of the Ala-Gln in the skin, and the amount of “natural” isocyanate scavengers in the skin (e.g., 
amino acids/peptides). 
Based on an in vitro human skin penetration study with Ala-Gln cream, if ~4% of the total 
applied Ala-Gln dose is recovered (see IB Section 4.3.1.1, Skin penetration study using whole 
human skin for additional information), this would represent the total amount of Ala-Gln 
available for reaction with isocyanate during penetration through the skin layers over time. 
Taking this into account, the required amount of Ala-Gln to be added would then correspond to a 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 17 - 
~3.91% (w/w) formulation instead of 0.16% (w/w) to account for retention of most of the 
product on the skin surface. Further, factoring in the apparent scavenging efficiency of Ala-Gln, 
which on the basis of the in vitro protein carbamylation assay using BSA as a model protein can 
be assumed to be ~65% (see IB Section 4.2.1.1, In vitro protein carbamylation inhibition assay), 
and also considering other factors such as potential degradation of Ala-Gln in the skin, then a 
dose strength of ~6.0% (w/w) would seem reasonable to ensure optimal scavenging effect 
towards isocyanate. However, currently available data only support physical-chemical stability 
of Ala-Gln in the MC2-25 cream up to 3% (w/w).  
The twice-daily dosing regimen has been chosen to compensate for the fact that the Ala-Gln 
strength in the MC2-25 cream may be at the lower end of the hypothetical efficiency range as 
explained above and because it is thought to be the highest feasible frequency for achieving both 
good treatment compliance and effect. 
There is no available data on the effect of MC2-25 vehicle in CKD-aP patients, and there are no 
approved medicinal products for topical treatment of CKD-aP.  Consequently, it is currently not 
possible to establish an expected vehicle effect size. In a clinical trial comparing IV 
administration of Korsuva® (i.e., the only approved treatment for CKD-aP in Europe; tradename 
Kapruvia®) and placebo for CKD-aP the reduction in weekly mean Worst Itch Numeric Rating 
Score (WI-NRS) from baseline to week 8 was approximately 2 in the placebo group (Spencer 
2018). The MC2-25-C1 trial is using a cream vehicle (and therefore has emollient properties) as 
control as opposed to a pure placebo control. Therefore, a reduction in weekly mean WI-NRS of 
at least 2 is expected in the MC2-25 vehicle arm in the MC2-25-C1 trial. 
The 12-week treatment duration was selected based on the assumption that if no differentiation 
to the MC2-25 vehicle is observed within that timeframe, then the treatment may be less 
clinically relevant. 
The primary endpoint assessment Worst Itch Numeric Rating Score (WI-NRS) was selected 
based on clinical and regulatory precedent with Korsuva® for CKD-aP and Dupixent® for 
another extremely itchy disease, namely AD. 
2.3 
Benefit-risk assessment 
As described above, CKD is a serious disease and patients with CKD often have dry and itchy 
skin with a major impact on their quality of life. While the benefits of MC2-25 cream are not yet 
known, an effective isocyanate scavenger Ala-Gln may reduce the adverse effects resulting from 
carbamylation of skin proteins and amino acids and thereby alleviate pruritus and dry skin in 
CKD-aP patients. 
A summary of risks that may be associated with the investigational medicinal product (IMP) 
MC2-25 cream or the trial procedures and mitigation strategies to address these is provided in 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 18 - 
Table 1. More detailed information about the risks associated with the IMP may be found in the 
IB. 
The MC2-25 cream is not authorised in EU or in other countries outside the EU. This is the first 
clinical trial with MC2-25 cream and MC2-25 vehicle so no clinical data are available. As noted 
above, the active ingredient Ala-Gln is included in the product Dipeptiven®, which has been 
approved for IV human use at doses up to 0.5 g per kg body weight per day. According to the 
Dipeptiven® SmPC (2015) there are no known undesirable effects when administered correctly. 
In the present trial a maximum of 50 g MC2-25 cream 3% (w/w) will be used per day, i.e., 0.5 g 
cream per 2% body surface area (see fingertip unit rule described above) and twice daily 
application. This corresponds to ~0.02 g Ala-Gln/kg/day (1.5 g Ala-Gln per day in a 70-kg adult) 
and a resulting safety margin of 25 compared to IV administration assuming that all topically 
applied Ala-Gln is absorbed into the systemic circulation. However, less than 1% of the total 
applied Ala-Gln dose was recovered in the receptor fluid (a surrogate for absorption into the 
systemic circulation) in an in vitro whole human skin penetration study with Ala-Gln cream (see 
IB Section 4.3.1.1, Skin penetration study using whole human skin). This corresponds to 
0.0002 g Ala-Gln/kg/day and a resulting systemic safety margin of 2500. Assuming that the skin 
defect in CKD-aP is similar to AD skin (worst case scenario), and consequently the skin 
permeation is 2.5-fold higher than in healthy skin (Yoshiike 1993), then the resulting systemic 
safety margin would be 10 or 1000 if either all or less than 1% of topically applied Ala-Gln was 
absorbed, respectively. In view of the benign safety profile of Dipeptiven® and the high safety 
margin, the risk of treatment-related systemic adverse effects is considered to be negligible in 
this trial.  
Ala-Gln is rapidly split into alanine and glutamine after infusion. In man, half-lives of between 
2.4 and 3.8 min (4.2 min in terminal renal insufficiency) and a plasma clearance of between 
1.6 and 2.7 l/min were determined (see IB Section 4.3, Pharmacokinetics and product 
metabolism in animals). So, even if topical application of MC2-25 cream leads to systemic 
exposure to Ala-Gln, then it will rapidly be metabolized to the two respective amino acids and 
become part of the body’s amino acid homeostasis. In view of the rapid elimination of any 
systemically available Ala-Gln, the risk of systemic drug-drug interactions is considered 
negligible in this trial. 
MC2-25 cream was safe and well tolerated when topically applied on a twice-daily basis for 
2 weeks in minipigs. All excipients used in MC2-25 cream are known from topical use in other 
drug products (references on internal file). Therefore, the risk of local adverse effects (local 
application site reactions) is considered to be low in this trial.   
A significant portion of CKD-ap patients in the trial are expected to be mid-aged to elderly and 
may have chronic comorbidities such as diabetes and hypertension. In view of the favourable 
safety profile, there are no eligibility criteria specific to the elderly population in this trial but 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 19 - 
exclusion criterion 10 ‘Has a concurrent or recent (within 12 months prior to screening) medical 
condition that, in the opinion of the investigator, could pose undue risk to the subject…..’ would 
ensure that any patients (including elderly) who are vulnerable due to comorbidities are not 
enrolled in the trial. Due to the general frailness of CKD-aP patients rather than any known or 
suspected side effects of the trial treatment, regular general safety monitoring in the form of 
physical examinations, vital signs measurements (systolic and diastolic blood pressure, pulse, 
and body temperature), safety blood samples (haematology and biochemistry), and ECGs are 
included in this trial. Patients will be enrolled through specialist nephrology sites experienced in 
the care for CKD patients including those who are elderly. 
In view of the major impact of CKD-aP on patient’s quality of life, the potential benefits of 
MC2-25 cream on CKD-aP, and the benign safety profile of MC2-25 cream, the benefit-risk 
ratio for the current trial is considered to be positive. 
Table 1: 
Summary of Risks and Mitigation Strategies 
Investigational Medicinal Product (MC2-25 cream) 
Risk Title: Application site 
reaction  
Risk Description: No application site reactions were observed after 
topical (dermal) application of MC2-25 cream and MC2-25 vehicle 
to minipigs (twice daily for 2 weeks). Consequently, the risk of 
application site reactions is considered low. However, in this trial 
MC2-25 cream and MC2-25 vehicle will be applied topically in 
humans for the first time. Therefore, at the present time application 
site reactions in humans cannot be ruled out. 
Risk Mitigation: The first IMP application will be performed in the 
clinic. Adverse events will be evaluated more frequently during the 
first 2 weeks of the trial treatment phase (weekly) compared to the 
subsequent weeks of the trial treatment phase (bi-weekly). In 
addition, a subject may withdraw from the trial or discontinue trial 
treatment at any time at his/her own request or at the discretion of 
the investigator due to unacceptable adverse events.  
Risk Title: Use during 
Pregnancy  
Risk Description: The toxicological profile of the active product 
ingredient Ala-Gln has been evaluated as part of the approval of 
Dipeptiven® with no indications of teratogenic or other embryotoxic 
and peri-postnatal injuries observed up to an intravenous dosage of 
1.6 g N(2)-L-alanyl-L-glutamine/kg body weight per day. 
Reproductive toxicity studies have not been conducted with 
MC2-25 cream. 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 20 - 
Risk Mitigation: According to the SmPC Dipeptiven® should not 
be administered during pregnancy due to lack of experience. 
Therefore, female subjects can only be randomized in the trial if 
they are of either non-childbearing potential or of childbearing 
potential and have a negative pregnancy test at the Baseline visit 
and use a highly effective method of contraception throughout the 
trial (see inclusion criteria for details). Due to the short half-life in 
plasma (<5 min), pregnancy testing is only mandatory while 
subjects receive double-blind treatment. 
Trial Procedures 
Risk Title: Blood sampling 
Risk Description: Blood sampling is invasive and there is always a 
slight risk of bruising, infections, pain, etc. 
Risk Mitigation: All blood sampling will be performed by trained 
staff and the volume of blood to be drawn at each occasion is small 
(approximately 10 mL). 
Risk Title: Tape stripping 
Risk Description: Repeated tape stripping may lead to transient, 
minor redness and irritation at the (̴ 4 cm2) tape stripping site.  
Risk Mitigation: If unacceptable redness and or irritation develops 
during the procedure, the procedure must be stopped. 
Risk Title: Skin biopsies 
Risk Description: As is the case with all invasive procedures, 
punch skin biopsies carry a small risk of bleeding and infection. In 
addition, a small scar may develop (Nischal 2008). 
Risk Mitigation: Skin biopsies will only be performed under sterile 
conditions by trained staff. Skin biopsies are optional and additional 
informed consent will be obtained from subjects who agree to have 
skin biopsies performed. Subjects will be informed about the risk of 
bleeding, infection, and scarring. In addition, subjects who will 
have skin biopsies performed must not have any diagnosed bleeding 
disorders or known hypersensitivity to the local anaesthetic used. 
Other 
Risk Title: Use of MC2-25 
vehicle  
Risk Description: One third of the subjects will be treated with 
MC2-25 vehicle during the 12-week treatment period. This might 
result in deterioration of CKD-aP. 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 21 - 
Risk Mitigation: Except for Remitch® in Japan and Korsuva® in 
US, no marketed products are approved for treatment of CKD-aP. 
Therefore, subjects will not miss out on approved treatment by 
participation in this trial. However, as described in Section 2.1.1, 
CKD-aP has a significant impact on quality of life and therefore 
off-label treatments are not uncommon. A recent Cochrane review 
concluded that, of all treatments for uremic pruritus, gabapentinoids 
(gabapentin and pregabalin) were the most studied and show the 
greatest reduction in itch scores (Hercz 2020). To limit the risk of 
deterioration of CKD-aP after entering the trial, all subjects are 
allowed to continue existing systemic treatment (including 
gabapentin and pregabalin) for CKD-aP during the trial, as 
described in more detail in exclusion criterion 13. Only one third of 
subjects will be randomized to receive the MC2-25 vehicle, which 
has emollient properties and as such is not strictly considered a 
placebo treatment. Subjects are free to withdraw from the trial or 
discontinue trial treatment at any time at their own request or at the 
discretion of the investigator in case of unacceptable adverse 
events. Withdrawal from the trial or discontinuation of trial 
treatment will not affect or prejudice the subject’s further care or 
treatment. 
Risk Title: COVID-19 
Risk Description: In view of the negligible risk of systemic 
adverse effects and/or drug-drug interactions, the risk of 
experiencing an aggravation of COVID-19 or experiencing 
interactions with COVID-19 vaccination is considered negligible in 
this trial. Consequently, subjects who have not been diagnosed with 
COVID-19 and do not have symptoms suggestive of COVID-19 
can safely be enrolled in the trial despite the ongoing pandemic and 
can follow COVID-19 vaccination programs. Subjects who have 
been diagnosed with or have symptoms suggestive of COVID-19 
carry a significant risk of transmitting the disease to other trial 
participants and trial staff.  
Risk Mitigation: All subjects will be asked to inform the site 
immediately (via phone – NOT in person!) if they are diagnosed 
with or have symptoms suggestive of COVID-19 and they will not 
be randomized (see exclusion criterion 10.d) and will not be 
allowed to attend trial visits until local COVID-19 regulations allow 
it. Subjects who are diagnosed with COVID-19 after randomization 
may subsequently be asked to complete trial visits (to the extent 
possible) via phone until applicable negative test results can be 
provided (if necessary, additional trial supplies may be shipped to 
the subject) or be withdrawn from the trial at the investigator’s 
discretion (see Section 5.4, Withdrawal from trial and 
discontinuation of treatment). COVID-19 diagnosis and/or 
COVID-19 vaccinations should be reported in the eCRF (as AEs or 
Concomitant therapies, respectively) to enable evaluation of any 
impacts on the safety of trial subjects or the integrity of trial data. 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 22 - 
 
3.0 
TRIAL OBJECTIVES AND PURPOSE 
The primary objective is to explore the clinical efficacy of MC2-25 cream compared to MC2-25 
vehicle in adults with chronic kidney disease-associated pruritus (CKD-aP). 
The secondary objectives are to explore the safety of MC2-25 cream compared to MC2-25 
vehicle in adults with CKD-aP and other objectives are to explore the subclinical effects of 
MC2-25 cream in adults with CKD-aP. 
4.0 
TRIAL DESIGN 
4.1 
Overall trial design 
This is a multicentre, phase 2, randomized, double-blind, 2-arm, parallel-group and vehicle-
controlled trial in subjects with CKD-aP. Approximately 108 eligible subjects will be 
randomised in a 2:1 ratio to MC-25 cream or MC2-25 vehicle, respectively. Subjects will apply 
the assigned IMP twice daily for 12 weeks.  
The overall trial duration for each subject is maximum 18 weeks. Subjects will be seen at the 
trial sites at Screening, Baseline, Week 1, Week 4, Week 8, and Week 12 (end of treatment, 
EoT). Subjects who have ongoing serious adverse events (SAEs) or related adverse events (AEs) 
at Week 12 will have a follow-up visit at Week 14 or (in case of early treatment discontinuation) 
14 days after the EoT visit, whichever comes first. Additionally, phone contacts are planned at 
Week 2, Week 6, and Week 10. 
 
Figure 1: 
MC2-25-C1 Clinical Trial Design 
 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 23 - 
4.2 
Trial endpoints 
Primary Objective:  
To explore the clinical 
efficacy of MC2-25 
cream compared to 
MC2-25 vehicle in 
adults with CKD-aP 
Primary Endpoint: 
• Mean change in weekly mean Worst Itch Numeric Rating 
Score (WI-NRS) recorded in the subject’s diary from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. (Weekly mean WI-NRS is calculated as the 
average of WI-NRS values recorded in the subject’s diary 
7 days prior to and including the visits.) 
Secondary Endpoints: 
• Percentage of subjects obtaining a ≥4-point improvement in 
weekly mean WI-NRS recorded in the subject’s diary from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. 
• Percentage of subjects obtaining a ≥3-point improvement in 
weekly mean WI-NRS recorded in the subject’s diary from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. 
• Percentage of subjects obtaining a complete response in 
weekly mean WI-NRS recorded in the subject’s diary from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. (Complete response is defined as scores 
equal to 0 or 1 in ≥80% of the non-missing WI-NRS values 
recorded in the subject’s diary 7 days prior to and including 
the visits.) 
Other Endpoints: 
• Mean change in WI-NRS recorded during on-site visits from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. 
• Mean change in Sleeploss due to Itch Numeric Rating Score 
(SI-NRS) from Baseline to Week 12 for MC2-25 cream 
compared to MC2-25 vehicle. 
• Mean change in Skin Dryness Numeric Rating Score 
(SD-NRS) from Baseline to Week 12 for MC2-25 cream 
compared to MC2-25 vehicle. 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 24 - 
• Percentage of subjects who reported “Much better” or 
“A little better” in Subject’s Global Impression of Change 
(SGIC) for Worst Itch (WI), Sleeploss due to Itch (SI), or 
Skin Dryness (SD) from Baseline to Week 12 for MC2-25 
cream compared to MC2-25 vehicle. 
• Percentage of subjects who reported an important 
improvement in SGIC for WI, SI, or SD at Week 12 for 
MC2-25 cream compared to MC2-25 vehicle. 
• Change in treatment area size from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle. 
• Change in 5D-Itch from Baseline to Week 12 for MC2-25 
cream compared to MC2-25 vehicle.  
• Change in Skindex-10 from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle. 
• Change in EQ-5D-5L from Baseline to Week 12 for MC2-25 
cream compared to MC2-25 vehicle. 
• Percentage of subjects obtaining a ≥2-step improvement in 
Clinician’s Global Assessment (CGA) of skin appearance 
from Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. 
• Percentage of subjects obtaining a ≥2-step improvement in 
one or more individual signs or in the Clinician’s Targeted 
Assessment (CTA) of skin appearance from Baseline to 
Week 12 for MC2-25 cream compared to MC2-25 vehicle. 
Secondary Objective: 
To explore the safety of 
MC2-25 cream 
compared to MC2-25 
vehicle in adults with 
CKD-aP 
Other Endpoints: 
• Frequencies of treatment-emergent adverse events (TEAEs), 
serious adverse events (SAEs), adverse drug reactions 
(ADRs), AEs leading to treatment discontinuation or trial 
withdrawal, and deaths during the trial for MC2-25 cream 
compared to MC2-25 vehicle. 
• Changes in mean safety assessments: vital signs (heart rate, 
systolic blood pressure, diastolic blood pressure, 
temperature) and blood samples (biochemistry, 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 25 - 
haematology) from Baseline to Week 12 for MC2-25 cream 
compared to MC2-25 vehicle. 
• Frequency of clinically significant abnormal physical 
examinations and ECGs from Baseline to Week 12 for 
MC2-25 cream compared to MC2-25 vehicle. 
• Percentage of subjects who missed 1 or more dialysis visits 
during the Double-blind Treatment Period. 
Other Objective: 
To explore the 
subclinical effects of 
MC2-25 cream 
compared to MC2-25 
vehicle in adults with 
CKD-aP 
Other Endpoints: 
• Changes in biomarkers in skin tape stripping samples from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. 
• Changes in biomarkers in skin punch biopsy samples from 
Baseline to Week 12 for MC2-25 cream compared to 
MC2-25 vehicle. 
 
5.0 
SELECTION OF TRIAL POPULATION 
5.1 
Subject population 
The trial population is males or non-pregnant females at least 18 years of age who have chronic 
kidney disease (CKD) stages G3-G5 (estimated glomerular filtration rate [eGFR] 
<60 mL/min/1.73 m2) and at least moderate CKD-aP (as defined in inclusion criterion 6). Both 
subjects on dialysis haemodialysis or haemodiafiltration and not on dialysis will be enrolled 
(=randomized). 
Subjects who fail screening because they do not meet minimum WI-NRS criteria cannot be 
re-screened. Subjects who fail screening for other reasons may be re-screened once. Reason(s) 
for screen failure will be recorded in the eCRF. Subjects fulfilling all inclusion and none of the 
exclusion criteria can be randomized in the trial. Pre-randomization approval of deviations to 
inclusion or exclusion criteria is not permitted. If deviations to inclusion or exclusion criteria are 
identified post-randomization, subjects shall continue in the trial as planned unless 
discontinuation of IMP treatment is warranted for safety reasons. 
5.2 
Inclusion criteria 
Subjects must meet all of the following criteria to be eligible for participation in the trial: 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 26 - 
1. 
Adult males or non-pregnant females of any race or ethnicity who are ≥ 18 years of age at 
the time of screening 
2. 
Able to understand the trial and willing to comply with trial requirements 
3. 
Has provided written informed consent 
4. 
Chronic (>3 months) kidney disease (CKD) stages G3-G5 (i.e., estimated glomerular 
filtration rate [eGFR] by CKD-EPI creatinine 2021 equation <60 mL/min/1.73 m2) 
5. 
Specifically for CKD subjects on haemodialysis (HD) or haemodiafiltration (HDF):  
a. 
Subjects must be established on HD or HDF 3 times per week continuously for at 
least 3 months prior to the start of screening (Note: at least the 2 last weeks of the 
3-month period must have been in-centre dialysis) and must not have plans to 
change from HD to HDF or vice versa during the trial. 
b. 
Subjects who require an occasional additional HD or HDF treatment to manage fluid 
overload may be enrolled as long as it is anticipated that no more than 4 such 
treatments will be required in any given month. 
6. 
At least moderate CKD-aP defined as WI-NRS ≥4 (i.e., the average of all and at least 
4 non-missing scores reported by the subject in the diary for 7 days prior to and including 
the Baseline day, 8 days in total) 
 
 
7. 
Female subjects must be of either: 
• Non-childbearing potential, i.e., postmenopausal* or confirmed sterile (e.g., 
hysterectomy, bilateral salpingectomy or bilateral oophorectomy).  
(*Note: a postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in women 
not using hormonal contraception or hormonal replacement therapy. However in the 
absence of 12 months of amenorrhea, a single FSH measurement is insufficient) or, 
• Childbearing potential with a negative highly sensitive urine pregnancy test at the 
Baseline visit or (in the case of anuria) a negative serum pregnancy test at the 
Baseline visit that is no more than 3 days old. 
8. 
Female subjects of childbearing potential must agree to use a highly effective method of 
contraception (i.e., a method with a failure rate of less than 1% per year when used 
consistently and correctly) while receiving double-blind treatment. Highly effective 
contraception is defined as follows:  


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 27 - 
• combined (estrogen and progestogen-containing) hormonal contraception 
associated with inhibition of ovulation: oral, intravaginal, transdermal 
• progestogen-only hormonal contraception associated with inhibition of ovulation: 
oral, injectable, implantable 
• intrauterine device (IUD) 
• intrauterine hormone-releasing system (IUS) 
• bilateral tubal occlusion 
• vasectomised partner (provided that is the sole sexual partner of the subject and that 
the vasectomised partner has received medical assessment of the surgical success) 
• sexual abstinence if in line with the preferred and usual lifestyle of the subject and 
defined as refraining from heterosexual intercourse during the entire period of the 
trial. Periodic methods of abstinence (e.g., calendar, ovulation, symptothermal, 
post-ovulation methods) are not accepted methods of contraception. 
5.3 
Exclusion criteria 
Subjects who fulfil any of the following criteria will be ineligible to participate in the trial: 
1. 
In the opinion of the investigator, the subject is unlikely to comply with the clinical trial 
protocol. 
2. 
Has a functioning kidney transplant or is scheduled to receive a kidney transplant during 
the trial (Note: subject can be on waiting list for kidney transplant) 
3. 
Subjects who receive peritoneal dialysis 
4. 
In the opinion of the investigator has pruritus attributed to a cause other than CKD or its 
complications, including but not limited to dermatological disease (e.g., atopic dermatitis, 
psoriasis) or liver disease (cholestatic pruritus) 
5. 
Has localized itch restricted to the palms of the hands 
6. 
Only has pruritus during haemodialysis sessions 
7. 
Has concurrent skin conditions (including but not limited to pruritic dermatoses, active 
skin infections, ulcerations) that may limit or prevent application of MC2-25 cream or 
MC2-25 vehicle or that may interfere with evaluation of the effects of MC2-25 cream or 
MC2-25 vehicle on the skin at the Screening or Baseline visits 
8. 
Subjects who will have skin biopsies performed must not have any known 
hypersensitivity to the local anaesthetic or diagnosed bleeding disorders. Note: subjects 
with suspected uremic platelet dysfunction, without other bleeding diatheses, can be 
enrolled if the investigator agrees. 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 28 - 
9. 
Known history of allergic reaction to any ingredients in MC2-25 cream or MC2-25 
vehicle (see Section 6.1) 
10. Has a concurrent or recent (within 12 months prior to screening) medical condition that, 
in the opinion of the investigator, could pose undue risk to the subject, impede completion 
of the trial procedures, or would compromise the validity of the trial measurements, 
including, but not limited to: 
a. known or suspected abuser of alcohol, drugs, or narcotic substances 
b. severe physical, mental, or cognitive disorder other than CKD 
c. malignancy 
d. failure to comply with local COVID-19 regulations on vaccination or testing (due to 
risk of transmitting the disease to other trial participants or trial staff). 
11. Has an uncontrolled Human Immunodeficiency Virus (HIV) or a known active 
generalized infection (bacterial, viral, or fungal) that, in the opinion of the investigator, 
may interfere with the assessment of safety or efficacy in this trial 
12. Is pregnant, breast feeding, or planning a pregnancy 
13. Start of a new or change to existing systemic treatment for CKD-aP, including but not 
limited to antihistamines, corticosteroids, opioids, GABA analogues, or kappa opioid 
receptor agonists within 21 days prior to the Baseline visit 
14. Use of emollients on CKD-aP areas within 10 days prior to the Baseline visit  
15. Use of any topical treatment on CKD-aP areas, including but not limited to 
antihistamines, or corticosteroids within 21 days prior to the Baseline visit (Note: 
standard topical treatments used on or around a haemodialysis access site are allowed, 
e.g., local anaesthetics, sterilants)  
16. Use of any light therapy for CKD-aP, including but not limited to UV-B within 35 days 
prior to the Baseline visit 
17. Start of a new or change of existing non-biologic systemic immunosuppressive treatment, 
including but not limited to corticosteroids, cyclosporin, and tacrolimus within 21 days 
prior to the Baseline visit  
18. Start of a new or change of existing biologic systemic treatment, including but not limited 
to etanercept, adalimumab, alefacept, infliximab, and ustekinumab within 3 months or 5 
half-lives (whichever is longer) prior to the Baseline visit  
19. Subjects who consent to having skin biopsies performed who are using anticoagulation 
treatment and are judged by the investigator to have an unacceptable risk of excessive 
bleeding in association with the skin biopsy  


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 29 - 
20. Subjects not currently on dialysis but who are likely to initiate routine dialysis during 
participation in the trial 
21. Received another investigational drug within 30 days or 5 half-lives (whichever is longer) 
prior to screening or is planning to participate in another clinical trial while enrolled in 
this trial 
22. Previously randomized in this trial 
5.4 
Withdrawal from trial and discontinuation of treatment 
In accordance with legal requirements and International Council for Harmonisation (ICH) – 
Good Clinical Practice (GCP) guidelines, every subject has the right to refuse further 
participation in this trial (withdrawal from trial) or refuse further treatment (discontinuation of 
treatment) at any time and without providing reasons. A subject's refusal should be effectuated 
immediately upon his/her request.  
In addition, a subject may be withdrawn from the trial or be discontinued from treatment at any 
time at the discretion of the investigator.  
Reasons for withdrawal from trial or discontinuation of treatment include (but are not necessarily 
limited to) progressive disease, AE, pregnancy, death, protocol violation, and lost to follow-up. 
If the IMP application is discontinued regardless of the reason for discontinuation, the subject 
should be encouraged to continue in the trial. 
The reasons for trial withdrawal or treatment discontinuation are to be fully documented on the 
electronic case report form (eCRF) and an EoT visit should be completed as soon as possible to 
the extent possible. Subjects who withdraw from trial before randomization will be considered 
screen failures. In case of treatment discontinuation, the subject should be encouraged to attend 
remaining trial visits in line with the schedule of assessments (SoA). If a subject is withdrawn 
from the trial due to an AE or treatment is discontinued due to an AE, the AE must be followed 
up as outlined in Section 7.12.2.  
If subjects are diagnosed with or have symptoms suggestive of COVID-19 they may not be 
allowed to attend trial visits until local regulations allow it. Subjects who are diagnosed with 
COVID-19 after randomization may subsequently be asked to complete trial visits (to the extent 
possible) via phone until applicable negative test results can be provided (if necessary, additional 
trial supplies may be shipped to the subject) or be withdrawn from the trial at the discretion of 
the investigator. 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 30 - 
5.5 
Replacement policy 
Subjects who discontinue treatment after the administration of the first dose of trial medication 
will not be replaced. See Section 7.13 for replacement of subjects missing assessments due to 
COVID-19. 
6.0 
TRIAL TREATMENTS 
6.1 
Investigational medicinal product 
MC2-25 cream 30 mg/g is a white oil-in-water, topical emulsion containing L-Alanyl-L-
Glutamine in the aqueous phase at concentrations of 3% (w/w). In addition to the active 
ingredient, the formulation contains Triglycerides medium chain, Paraffin liquid, Glycerol, 
Carbomer interpolymer type A, Phenoxyethanol, Macrogol lauryl ether (4), Citric acid, Sodium 
Benzoate, Polysorbate (20), Sodium hydroxide, and Purified water. 
6.2 
Vehicle product 
MC2-25vehicle is identical to the IMP except for the active ingredient. 
6.3 
Dosing regimen 
MC2-25 cream or MC2-25 vehicle is to be applied twice daily, in the morning and evening, to 
areas with CKD-aP. The treatment must be applied in a thin even layer to affected areas and 
rubbed in gently to ensure that the treatment areas are saturated. Treatment of all areas with 
CKD-aP must be continued until the Week 12 (or EoT) visit. This is also applicable for areas 
becoming itch-free during trial participation and new areas of CKD-aP identified after the 
Baseline visit.   
The daily dose should not exceed 50 g. Detailed application instructions will be provided in the 
subject instructions. 
6.4 
Dose modification 
Not applicable. 
6.5 
Packaging, labelling and storage 
MC2-25 cream and MC2-25 vehicle are identical in appearance and packaging. 
Medication labels for the IMPs will comply with the legal requirements of the country where the 
trial is performed and be printed in the local language.  
The IMPs will be supplied by MC2’s designated vendor and will be stored securely at the site 
under the control of the investigator. The temperature will be monitored and documented.    


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 31 - 
The IMP will be supplied to the clinical site(s) as tubes containing 60 g of product. The IMP is to 
be stored at a temperature of 2° to 8°C at the site, and below 25°C after dispensing to the subject. 
At all times, the IMP tube should be protected from direct sunlight exposure.  
6.6 
Assignment to treatment 
6.6.1 
Randomisation 
Randomisation will be performed using a validated system that automates the random 
assignment of treatment groups to randomisation numbers. Treatment assignment will be via a 
central interactive web response (IWR) system in accordance with a pre-planned computer-
generated randomisation schedule in a 2:1 ratio.  
Randomisation will be stratified according to the following CKD stage strata:  
A. ≥40% of subjects must be on dialysis (HD or HDF) and must be CKD stages 4-5 
B. ≥20% of subjects must Not be on dialysis and must be CKD stages 4-5 
C. ≥20% of subjects must Not be on dialysis and must be CKD stage 3 
Randomisation data will be kept strictly confidential, accessible only to authorised persons, until 
the time of unblinding. 
A subject who fulfils the trial eligibility requirements will be randomly assigned to treatment. 
6.6.2 
Blinding 
This is a double-blind trial. The sponsor, sponsor representatives, and all subjects, monitors, and 
trial personnel will be blinded throughout the trial. Instructions for emergency unblinding are 
provided in Section 13.1. 
6.7 
Prior, concomitant, and prohibited therapies 
Medications and therapies are hereafter referred to as therapies. All therapies (i.e., prescription 
drugs [including COVID-19 vaccination programs, see Table 1], dialysis treatment regimen, 
over-the-counter [OTC] drugs and vitamins, herbal and dietary supplements) taken within 
30 days prior to screening will be recorded as prior therapies at the Screening visit.  
Thereafter, all therapies used during the course of the trial will be recorded as concomitant 
therapies. Information regarding the total daily dose, route of administration, start and 
discontinuation dates, and indication are to be recorded on the subject’s eCRF. 
 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 32 - 
6.7.1 
Prohibited therapies prior to baseline 
A number of therapies are prohibited during the period leading up to baseline as outlined in 
Table 2.  
Table 2: 
Prohibited Therapies Prior to Baseline 
Prohibited Therapy 
Exclusion 
Criterion 
Applicable Period 
Prior to Baseline (Day 
0) 
Start of a new or a change to existing systemic treatment for 
CKD-aP, including but not limited to antihistamines, 
corticosteroids, opioids, GABA analogues, or kappa opioid 
receptor agonists (Section 5.3).  
13 
21 days 
Use of emollients on CKD-aP areas within 10 days prior to the 
Baseline visit 
14 
10 days 
Use of any topical treatment on CKD-aP areas, including but 
not limited to antihistamines, or corticosteroids. Note: standard 
topical treatments used on or around a haemodialysis access 
site are allowed, e.g., local anaesthetics, sterilants.  
15 
21 days 
Use of any light therapy for CKD-aP, including but not limited 
to UV-B 
16 
35 days 
Start of new or change of existing non-biologic systemic 
immunosuppressive treatment, including but not limited to 
corticosteroids, cyclosporin, and tacrolimus.  
17 
5 weeks 
Start of new or change of existing biologic systemic treatment, 
including but not limited to etanercept, adalimumab, alefacept, 
infliximab, and ustekinumab  
18 
3 months or 5 half-lives 
(whichever is longer) 
 
Therapies not listed are allowed. 
6.7.2 
Prohibited therapies from baseline to the end of the treatment period 
Use of any therapy that would exclude the subject from participation in the trial (as specified in 
Section 5.3) is also prohibited during the treatment period, which includes therapies in the 
following categories:  
• 
Start of new or change of existing systemic treatment for CKD-aP, including but not 
limited to antihistamines, corticosteroids, opioids, GABA analogues, or kappa opioid 
receptor agonists (but stable systemic CKD-aP treatment can be continued). 
• 
Any topical treatment on CKD-aP areas, including but not limited to emollients, 
antihistamines, and corticosteroids 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 33 - 
• 
Therapeutic anticoagulation treatment for subjects who have skin biopsies performed 
(heparin administered in association with dialysis is allowed but in such cases skin 
biopsies must not be performed on a dialysis day) 
• 
Any light therapy for CKD-aP, including but not limited to UV-B 
• 
Start of new or change of existing non-biologic systemic immunosuppressive treatment, 
including but not limited to corticosteroids, cyclosporin and tacrolimus  
• 
Start of new or change of existing biologic systemic treatment, including but not limited 
to etanercept, adalimumab, alefacept, infliximab, and ustekinumab 
If a prohibited therapy is used during the trial, treatment with the IMP shall not automatically be 
discontinued. After consultation with the sponsor’s or designee’s Medical Monitor, the 
investigator shall use his/her judgement to decide if (in the following prioritized order) 1) The 
prohibited therapy can safely be stopped; 2) the prohibited therapy cannot safely be stopped but 
the IMP treatment can safely continue alongside the prohibited therapy; or 3) the prohibited 
therapy cannot safely be stopped and the IMP treatment cannot safely continue alongside the 
prohibited therapy. The event must be reported as a protocol deviation.  
6.8 
Therapies not listed are allowed. Treatment compliance and drug accountability 
Records of trial product used, and dosages administered will be kept during the trial. The trial 
monitor will note product accountability during site visits and at the completion of the trial. 
Subjects will be asked to return all used and unused tubes in the outer box at each visit to ensure 
drug accountability. All returned tubes that had been dispensed to a subject and have broken 
seals will be weighed to determine the amount of the IMP.  
At all on-treatment visits, the subject will be asked if he/she has used the trial medication as 
prescribed and to indicate the CKD-aP treatment area size. Any degree and nature of 
noncompliance will be specified. In addition, subjects will be asked to complete a dosing diary 
during the treatment period as a measure of treatment compliance. Subjects who are consistently 
noncompliant will be counselled. 
 
 


Protocol No. MC2-25-C1 
Vers.3.0_EU/30-Nov-2022 
 
Clinical Trial Protocol 
 
MC2 Therapeutics  
 
- 34 - 
 
7.0 
VISIT SCHEDULE AND ASSESSMENTS 
7.1 
Visit schedule  
The schedule of assessments (SoA) is provided in Table 3. 
The informed consent process must be completed before any other assessment or procedure. The 
following order of assessments must always be adhered to:  
• Patient Reported Outcomes should be assessed before all other clinical assessments or 
procedures. 
• Skin tape stripping and skin biopsies of CKD-aP target areas must be taken after imaging 
and CTA of CKD-aP target areas. 
On-site visit days should preferably be on the same weekday throughout the trial for subjects on 
dialysis. On-site visits should be aligned with dialysis visits to the extent possible to avoid 
unnecessary travelling for subjects on dialysis.


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
 
MC2 Therapeutics  
 
- 35 - 
Table 3: 
Visit Schedule 
Trial Period 
Screening 
Period 
Treatment Period 
FU 
period1 
Visit Number2 
1 
(Screening) 
2  
(Baseline) 
3 
4 
5 
6 
7 
8 
9 
(EoT)3  
10 
(FU) 
Trial Week 
 
0 
1 
2 
4 
6 
8 
10 
12 
14 
Days from Baseline (Visit 2) 
Visit Window 
-28 to -1 
NA 
0 
NA 
7 
±1 
14 
±2 
28 
±4 
42 
±2 
56 
±4 
70 
±2 
84 
±4 
 
±2 
In-clinic or Phone Visits4 
In-Clinic 
In-Clinic 
In-
Clinic Phone 
In-
Clinic Phone 
In-
Clinic Phone 
In-
Clinic 
In-
Clinic 
Informed Consent5 
X 
 
 
 
 
 
 
 
 
 
Eligibility Assessment 
X 
X 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
CKD History 
X 
 
 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
 
CKD-aP Treatment History 
X 
 
 
 
 
 
 
 
 
 
Worst Itch NRS (WI-NRS) – at-home (diary) assessments6 
 
X 
X 
 
X 
 
X 
 
X 
 
Worst Itch NRS (WI-NRS) – On-site assessment7, 8 
X 
X 
X 
 
X 
 
X 
 
X 
 
Sleeploss due to Itch NRS (SI-NRS)8  
X 
X 
X 
 
X 
 
X 
 
X 
 
Skin Dryness NRS (SD-NRS)8  
X 
X 
X 
 
X 
 
X 
 
X 
 
Subject’s Global Impression of Change (SGIC)8 
 
 
X 
 
X 
 
X 
 
X 
 
Subject´s rating of importance of improvement8 
 
 
X 
 
X 
 
X 
 
X 
 
Subject’s indication of CKD-aP treatment area size8, 9 
 
X 
X 
 
X 
 
X 
 
X 
 
5D-Itch8  
 
X 
 
 
X 
 
X 
 
X 
 
Skindex-108 
 
X 
 
 
X 
 
X 
 
X 
 
EQ-5D-5L8 
 
X 
 
 
X 
 
X 
 
X 
 
CKD-aP target area identification 
 
X 
 
 
 
 
 
 
 
 
CGA of Skin Appearance 
X 
X 
X 
 
X 
 
X 
 
X 
 
CTA of Skin Appearance 
 
X 
X 
 
X 
 
X 
 
X 
 
Physical examination10 
X 
X 
 
 
 
 
 
 
X 
(X) 
Vital signs11 
X 
X 
 
 
X 
 
X 
 
X 
(X) 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
 
MC2 Therapeutics  
 
- 36 - 
Trial Period 
Screening 
Period 
Treatment Period 
FU 
period1 
Visit Number2 
1 
(Screening) 
2  
(Baseline) 
3 
4 
5 
6 
7 
8 
9 
(EoT)3  
10 
(FU) 
Trial Week 
 
0 
1 
2 
4 
6 
8 
10 
12 
14 
Days from Baseline (Visit 2) 
Visit Window 
-28 to -1 
NA 
0 
NA 
7 
±1 
14 
±2 
28 
±4 
42 
±2 
56 
±4 
70 
±2 
84 
±4 
 
±2 
Single 12-lead ECG 
 
X 
 
 
X 
 
 
 
X 
(X) 
Pregnancy Testing12 
X 
X 
 
 
X 
 
 
 
X 
(X) 
Laboratory Assessments13 
X 
X 
 
 
X 
 
 
 
X 
(X) 
Imaging of CKD-aP14 
 
X 
 
 
X 
 
 
 
X 
 
Randomisation 
 
X 
 
 
 
 
 
 
 
 
Diary (Handout) 
X 
X 
X 
 
X 
 
X 
 
 
 
Biopsy15 
 
X 
 
 
 
 
 
 
X 
 
Tape stripping16 
 
X 
 
 
 
 
 
 
X 
 
Prior & concomitant therapies17 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational medicinal product (IMP) dispensation 
 
X 
 
 
X 
 
X 
 
 
 
IMP return, compliance and accountability 
 
 
 
 
X 
 
X 
 
X 
 
IMP application18 
 
X 
 
Diary (Review) 
 
X 
X 
 
X 
 
X 
 
X 
 
 
1. Follow-up (FU) visit is only applicable if there are ongoing serious adverse events (SAEs) or related adverse events (AEs) at Week 12. (X) indicates 
assessments to be performed if judged necessary by the investigator. 
2. An unscheduled visit can be conducted to perform any of the postbaseline assessments or procedures included in the SoA if deemed necessary by the 
Investigator. 
3. In the case of trial withdrawal or treatment discontinuation, all assessments of the Week 12 (End of Treatment [EoT]) visit have to be performed. The 
end of treatment form must be completed when treatment is discontinued and the end of trial form must be completed at end of the trial or in case of 
trial withdrawal.  
4. Phone calls: To remind subjects about diary documentation (in particular once-daily WI-NRS assessments that must be performed for 8 days leading 
up to each on-site visit [i.e., from day -7 to day 0 where day 0 = next on-site visit day]) and to ask for AEs. Phone visits may be replaced by in-clinic 
visits where relevant, e.g., in subjects going to the dialysis unit for haemodialysis. 
5. Informed consent must be signed by both subject and investigator before any trial-related procedures are performed. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
 
MC2 Therapeutics  
 
- 37 - 
6. At-home (diary) assessments must be performed for 8 days leading up to each visit, i.e., from day -7 to day 0 where day 0 = next on-site visit day. 
7. The WI-NRS must also be reported by the subject at on-site visits  
8. At all on-site visits, all patient-reported outcome (PRO) assessments should be completed before all other clinical assessments or procedures. 
9. The trial staff must estimate the % body surface area treated based on the subject’s indication of CKD-aP treatment area size on the CKD-aP treatment 
area diagram. 
10. Physical exam: A complete physical examination is required at Screening and Week 12 (EoT or Early Termination) visits. An abbreviated physical 
examination is required at the Baseline visit (and if judged necessary by the investigator) at the FU visit if the FU visit is applicable.  
11. Vital signs include blood pressure, heart rate, and body temperature measurement. For subjects on haemodialysis vital signs are to be assessed prior to 
dialysis. Blood pressure and pulse rate will be taken with the subject in the sitting position with approximately 5 minutes rest prior to measurement.  
12. Serum pregnancy tests are conducted for women of childbearing potential. At Baseline a urine pregnancy test must also be conducted except for 
dialysis subjects with anuria.  
13. For subjects on dialysis, the blood samples must be collected before dialysis.  
14. Only at selected sites and only for subjects who have provided additional consent. CKD-aP target area selected at Baseline. Images of CKD-aP target 
area must be taken before tape stripping and skin biopsies. 
15. Only at selected sites and only for subjects who have provided additional consent. Biopsy: 4 mm skin punch biopsy (optional) is taken from the 
CKD-aP target area.  
16. Tape stripping is conducted in all subjects from the CKD-aP target area. 
17. “Therapies” refers to medications and therapies. 
18. The first IMP application shall preferably be performed in the clinic under surveillance, and assistance if necessary, of trial staff. 
 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 38 - 
7.2 
Demographics and medical history 
The following demographic and medical history must be collected in the eCRF:  
• Year of birth 
• Sex 
• Race 
• Subject-reported ethnicity 
• CKD stage and history, including age of diagnosis, severity, and in subjects on 
haemodialysis (HD or HDF), information on haemodialysis 
• All other current and past medical/surgical conditions within the previous 12 months 
 
7.3 
Prior and concomitant therapies 
Prior or concomitant therapies as defined in Section 6.7 must be recorded in the eCRF at all trial 
visits. Information regarding the total daily dose, route of administration, start and 
discontinuation dates, and indication are to be recorded on the subject’s eCRF. 
7.4 
Physical examination 
A complete physical examination (i.e., including all organ systems as well as the skin) is 
required at Screening and Week 12 or (EoT or Early termination). The height and weight can be 
self-reported. An abbreviated physical examination (i.e., including the skin as a minimum; other 
organ systems may be included depending on present signs, symptoms or investigation 
outcomes) is conducted at Baseline. For subjects with SAEs or ongoing related AEs at Week 12, 
an abbreviated physical examination is also conducted at Week 14 (Follow-up) if judged 
necessary by the investigator.  
Any abnormalities must be assessed as “clinically significant” or “not clinically significant” by 
the investigator. Abnormalities classified as “clinically significant” must be recorded in the 
eCRF as AEs except those observed at Screening visit 1, which will be recorded as medical 
history. 
7.5 
Vital signs 
Vital signs must be recorded in the eCRF. Vital signs (systolic and diastolic blood pressure, heart 
rate, and body temperature) will be measured at Screening, Baseline, Week 4, Week 8, and 
Week 12 (EoT or Early Termination) visits. For subjects with ongoing SAEs or related AEs at 
Week 12, vital signs are also measured at Week 14 (Follow-up) if judged necessary by the 
investigator. In haemodialysis subjects, vital signs are to be recorded prior to dialysis. Blood 
pressure and heart rate will be taken with the subject in the sitting position with approximately 
5 minutes rest prior to measurement. Body temperature (oral or ear) will also be measured.  


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 39 - 
Any abnormalities must be assessed as “clinically significant” or “not clinically significant” by 
the investigator. Abnormalities classified as “clinically significant” must be recorded in the 
eCRF as AEs except those observed at Screening visit 1, which will be recorded as medical 
history. 
7.6 
Electrocardiogram (ECG) 
A single 12-lead ECG must be recorded using local equipment at Baseline, Week 4, and 
Week 12 or Early Termination. For subjects with ongoing SAEs or related AEs at Week 12, a 
single 12-lead ECG will also be performed at Week 14 (Follow-up) if judged necessary by the 
investigator. In haemodialysis subjects, ECGs are to be performed preferably prior to dialysis. 
Interpretation of ECGs will be based on machine read-out and local physician evaluation 
(cardiologist overread will not be performed). 
Any abnormalities must be assessed as “clinically significant” or “not clinically significant” by 
the investigator. Abnormalities classified as “clinically significant” must be recorded in the 
eCRF as AEs except those observed at Screening visit 1, which will be recorded as medical 
history. 
7.7 
Pregnancy test 
Women of childbearing potential will undergo a serum pregnancy test at Screening, Baseline, 
Week 4, and Week 12 or Early Termination. At Baseline a highly sensitive urine pregnancy test 
(i.e. with sensitivity down to at least 25 mIU/ml for human chorionic gonadotrophin (hCG)) must 
also be conducted except in dialysis subjects with anuria. At the investigator’s discretion, 
additional testing for pregnancy may be performed at the FU visit if this visit is applicable.  
All pregnancies must be recorded in the eCRF and should be immediately reported to the 
sponsor or designee and followed through to resolution (i.e., delivery, miscarriage, or abortion). 
The report should be submitted within the same timelines as an SAE (within 24 hours of 
knowledge), although a pregnancy per se is not considered an SAE.  
7.8 
Laboratory assessments 
Clinical laboratory specimens will be analysed by a central licensed and accredited laboratory 
facility according to the laboratory’s standard operating procedures.  
Any abnormalities must be assessed as “clinically significant” or “not clinically significant” by 
the investigator. Abnormalities classified as “clinically significant” must be recorded in the 
eCRF as AEs except those observed at Screening visit 1, which will be recorded as medical 
history. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 40 - 
7.8.1 
Haematology and biochemistry 
For all subjects, the following tests will be performed at Screening, Baseline, Week 4, and 
Week 12 or Early Termination. For subjects with ongoing SAEs or related AEs at Week 12, 
laboratory tests will also be performed at Week 14 (Follow-up) if judged necessary by the 
investigator. In patients on dialysis, the blood samples must be collected before dialysis: 
• Haematology: haemoglobin, haematocrit, red blood cell (RBC) count, mean corpuscular 
volume (MCV), and white blood cells (WBC) count (basophils, eosinophils, neutrophils, 
lymphocytes, and monocytes), including differential count and platelet count  
• Serum biochemistry: urea, creatinine, albumin, sodium, potassium, chloride, calcium, 
phosphate, alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine 
aminotransferase (ALT) 
7.9 
Patient-reported outcome (PRO) assessments 
At all in-clinic visits, all PRO assessments should be completed before other clinical assessments 
and procedures. 
7.9.1 
Worst itch numeric rating score (WI-NRS) 
The subject’s WI-NRS must be recorded by the subject in a diary once daily (at the same time of 
the day throughout the trial, i.e., morning, afternoon, or evening for all recordings) on day -7 to 
day 0 (where day 0 = next on-site visit day) leading up to each visit (8 days in total) at Baseline, 
Week 1, Week 4, Week 8, and Week 12 or Early Termination using an 11-point numeric rating 
scale ranging from 0 to 10: 
Please score the intensity of the Worst Itch you have experienced in the past 24 hours: 0 (no 
itch), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (very severe/extreme itch). 
In addition, the subject’s WI-NRS must be evaluated at on-site visits at Screening, Baseline, 
Week 1, Week 4, Week 8, and Week 12 or Early Termination using the 11-point verbal rating 
scale above. 
7.9.2 
Sleeploss due to itch numeric rating score (SI-NRS) 
The subject’s SI-NRS must be evaluated at Screening, Baseline, Week 1, Week 4, Week 8, and 
Week 12 or Early Termination using an 11-point numeric rating scale ranging from 0 to 10: 
Please score how much Sleeploss due to Itch you have experienced in the past 24 hours: 0 (no 
sleeploss due to itch), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (very severe/extreme sleeploss due to itch). 
7.9.3 
Skin dryness numeric rating score (SD-NRS) 
The subject’s SD-NRS must be evaluated at Screening, Baseline, Week 1, Week 4, Week 8, and 
Week 12 or Early Termination using an 11-point numeric rating scale ranging from 0 to 10: 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 41 - 
Please score the intensity of the Worst Skin Dryness you have experienced in the past 24 hours 
in the areas treated with trial medication: 0 (no skin dryness) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (very 
severe/extreme skin dryness). 
7.9.4 
Subject’s global impression of change (SGIC) 
SGIC in Worst Itch (WI), Sleeploss due to Itch (SI), and Worst Skin Dryness (SD) must be 
evaluated at Week 1, Week 4, Week 8, and Week 12 or Early Termination using a 7-item verbal 
rating scale: 
Please choose the response below that best describes the overall change in your (Worst Itch*) 
since you started taking the trial medication: 
• Very much better 
• Much better 
• A little better 
• No change 
• A little worse 
• Much worse 
• Very much worse 
*SGIC must be repeated with SI and SD. 
7.9.5 
Subject’s rating of importance of improvement  
Subjects reporting an improvement in SGIC (“Very much better,” “Much better,” or “A little 
better”) must rate the importance of improvements in WI, SI, and SD at Week 1, Week 4, 
Week 8, and Week 12 or Early Termination using a 2-item Importance Questionnaire: 
Question 1:You have reported an improvement in your (Worst Itch*) since you started taking the 
trial medication. Was the improvement important to you? (Yes/No). If yes, please proceed to 
question 2. 
Question 2: In which way(s) was the improvement in your (Worst Itch*) important to you? (free 
text) 
*Subject’s rating of importance of improvements must be repeated with SI and SD. 
7.9.6 
Health-related quality of life (HRQoL)  
HRQoL must be evaluated by the subject at Baseline, Week 4, Week 8, and Week 12 or Early 
Termination using the Skindex-10, 5D-Itch and EQ-5D-5L questionnaires. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 42 - 
7.9.6.1 
Skindex-10 
The Skindex-10 consists of 10 questions (beginning with “During the past week, how often have 
you been bothered by…..”) exploring the impact of itch on 3 domains (disease, mood/emotional 
distress and social functioning) with a 1 week recall period.  
Each question must be scored on a 7-point scale ranging from 0 (never bothered) to 6 (always 
bothered).  
The domain scores are the sums of the following: disease domain (questions 1 to 3), 
mood/emotional distress domain (questions 4 to 6), and social functioning domain (questions 7 
to 10). 
The total score is the sum of the numeric value of each answered question. The total score ranges 
from 0 to 60. 
7.9.6.2 
5D-Itch 
The 5D-Itch consists of 5 domains numbered 1-5. Domains 1-3 are single item (question) 
domains exploring the Duration (Duration domain), Degree (Degree domain) and Direction 
(Direction domain) of Itch. Domain 4 (Disability domain) includes four items (questions) 
assessing the impact of itching on daily activities: sleep, leisure/social activities, 
housework/errands and work/school). Domain 5 (Distribution domain) assesses the number of 
affected body parts out of 16 possible options. For each of domains 1-3 the domain score is equal 
to the value indicated below the response choice (range 1–5). For domain 4 the score is achieved 
by taking the highest score on any of the four items (range 1-5). For domain 5 the score is 
obtained by tallying the number of affected body parts and the sum is sorted into five scoring 
bins: sum of 0–2 = score of 1, sum of 3–5 = score of 2, sum of 6–10 = score of 3, sum of 
11-13 = score of 4, and sum of 14-16 = score of 5 (range 1-5). 
The total score is achieved by summing together the 5 domain scores and can therefore range 
between 5 (no pruritus) and 25 (most severe pruritus).  
7.9.6.3 
EQ-5D-5L 
The EuroQoL 5 Dimensions, 5 levels (EQ-5D-5L) is a generic, multidimensional, health-related, 
quality-of-life instrument and comprises a Visual Analogue Scale (VAS) and a short descriptive 
system questionnaire.  
The VAS records the subject’s overall current health on a vertical VAS where the endpoints are 
labelled “(100) The best health you can imagine” and “(0) The worst health you can imagine.” 
The VAS provides a quantitative measure of the subject’s perception of his/her overall health. 
The descriptive system questionnaire allows subjects to rate their health in 5 domains: mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression using a 5-level scale 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 43 - 
indicating: 1. no problem, 2. slight problem, 3. moderate problem, 4. severe problem, or 
5. unable to/extreme problems. The perceived problem levels for each domain are combined into 
a 5-digit health state that is converted to an index value, which reflects how good or bad a health 
state is according to the preferences of the general population with higher scores indicating better 
quality of life. 
7.9.7 
Subject’s indication of CKD-aP treatment area size 
The subject must indicate the size of the CKD-aP treatment area (by greying out all areas treated) 
at Baseline, Week 1, Week 4, Week 8, and Week 12 or Early Termination using the CKD-aP 
treatment area diagram below, if necessary, with assistance from trial staff. Subsequently, trial 
staff must estimate the size of the treatment area (in terms of % body surface area treated) based 
on the CKD-aP treatment area diagram: 
CKD-aP treatment area diagram – according to subject (example) 
 
 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 44 - 
7.10 
Clinician-reported outcome (ClinRO) assessments 
7.10.1 
Identification of CKD-aP target area 
At the Baseline visit a CKD-aP target area that fulfils the following criteria must be identified by 
trained clinical staff: 
• 
The area must be among the areas with the worst CKD-aP according to the subject 
• 
The area must measure minimum 10 cm x 10 cm in size (roughly the palm of a hand) 
• 
The area must be easy for the subject to reach, to apply the IMP on and must be treated 
with the IMP throughout the double-blind treatment phase of the trial 
• 
The area must not be in close proximity of dialysis access sites in haemodialysis subjects 
When the CKD-aP target area has been identified it must be marked with a square on the “CKD-aP 
diagram.” An example of a CKD-aP target area marked with an asterisk * is shown on the CKD-aP 
diagram below. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 45 - 
CKD-aP target area diagram (*example of CKD-aP target area) 
 
7.10.2 
Clinician’s global assessment (CGA) of skin appearance 
CGA of skin appearance on the entire body surface area must be evaluated by trained clinical 
staff (preferably the same staff member throughout the trial for an individual subject) and 
recorded in the eCRF at Screening, Baseline, Week 1, Week 4, Week 8, and Week 12 or Early 
Termination using a 5-point verbal rating scale (from clear to severe) as follows: 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 46 - 
Please choose the description below that best describes the severity of skin dryness and skin 
signs of itch on the entire body surface area: 
CGA score 
Skin Dryness Description 
Skin signs of Itch Description 
Clear 
No skin dryness   
No active skin signs of itch* 
(chronic skin signs of itch may be 
present) 
Almost clear 
Barely perceptible skin dryness  
Barely recognizable active skin 
signs of itch*  
Mild 
Easily perceptible skin dryness  
Easily recognizable active skin signs 
of itch*  
Moderate 
Moderate [between Mild and 
Severe] skin dryness 
Moderate [between Mild and 
Severe] active skin signs of itch*  
Severe 
Marked skin dryness 
Marked active skin signs of itch*  
*Active skin signs of itch include but are not necessarily limited too excoriation, crusting, 
superficial bleeding or intradermal bleeding (ecchymoses) or prurigo nodules and must be 
distinguished from chronic skin signs of itch, e.g., skin discoloration, thickening or scarring. 
 
The overall CGA intensity is defined based on the intensity of the individual signs skin dryness 
and skin signs of itch. In case of difference in intensity of skin dryness and skin signs of itch then 
the worst intensity shall prevail in the overall CGA score (e.g., in case of mild skin dryness and 
severe skin signs of itch, then the overall CGA must be scored as severe). 
7.10.3 
Clinician’s targeted assessment (CTA) of skin appearance 
CTA of skin appearance in the CKD-aP target area (see Section 7.10.1 for description of CKD-
aP target area) must be evaluated by trained clinical staff (preferably the same staff member 
throughout the trial for an individual subject) and recorded in the eCRF at Baseline, Week 1, 
Week 4, Week 8, and Week 12 or Early Termination. CTA includes assessments of skin dryness 
and skin signs of itch and overall CTA in the CKD-aP target area using a 5-point verbal rating 
scale (from clear to severe) as follows: 
Please choose the description below that best describes the skin dryness and skin signs of itch on 
the CKD-aP target area: 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 47 - 
CTA score 
Skin Dryness Description 
Skin Signs of Itch Description 
Clear 
No skin dryness 
No active skin signs of itch* 
(chronic skin signs of itch may be 
present) 
Almost clear 
Barely perceptible skin dryness  
Barely recognizable active skin 
signs of itch*  
Mild 
Easily perceptible skin dryness  
Easily recognizable active skin signs 
of itch*  
Moderate 
Moderate (between Mild and 
Severe) skin dryness 
Moderate (between Mild and 
Severe) active skin signs of itch*  
Severe 
Marked skin dryness 
Marked active skin signs of itch*  
*Active skin signs of itch include but are not necessarily limited to excoriation, crusting, 
superficial bleeding or intradermal bleeding (ecchymoses), or prurigo nodules and must be 
distinguished from chronic skin signs of itch, e.g., skin discoloration, thickening, or scarring. 
 
The overall CTA intensity is defined based on the intensity of the individual skin dryness and 
skin signs of itch assessments. In case of difference in intensity of skin dryness and skin signs of 
itch then the worst intensity shall prevail in the CTA score (e.g., in case of mild skin dryness and 
severe skin signs of itch, then the overall CTA must be scored as severe). 
7.10.4 
Imaging of CKD-aP  
Imaging of the CKD-aP target area (see Section 7.10.1 for description of CKD-aP target area) 
will be obtained by the trained clinical staff at Baseline, Week 4, and Week 12 or Early 
Termination in a subset of subjects who provide additional consent. The same area must be used 
for imaging at the subsequent timepoints indicated in the SoA. Images must always be taken 
before skin tape stripping and skin biopsies.  
The imaging procedure will be described in a separate manual. Steps will be taken to ensure that 
the identities of the subjects are protected. Additional informed consent will be obtained with 
regard to collection, transmission and use of images. 
7.11 
Biomarker assessments of CKD-aP  
The subclinical effects of MC2-25 on CKD-aP will be evaluated by analyses of relevant 
biomarkers in skin biopsies and skin tape strips after completion of the trial.  
Skin tape stripping provides information on biomarker changes in the most superficial layer of 
the skin, i.e., the stratum corneum, which is the uppermost part of the epidermis. In contrast, a 
skin biopsy can provide information on biomarker changes through all layers of the skin, i.e., the 
epidermis and the dermis. As this trial is the first in humans with the MC2-25 cream it is 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 48 - 
important to understand not only whether the treatment has effects on biomarkers in the skin but 
also to understand to which skin depth such effects extend.  
7.11.1 
Skin biopsies 
Skin biopsies will be obtained (at selected trial sites) by a physician at Baseline and Week 12 or 
Early Termination (after the Week 4 visit) in a subset of subjects who provide additional consent 
to have skin biopsies performed.  
Skin biopsies will be taken from the upper right quadrant at the Baseline visit and from the upper 
left quadrant at the Week 12 (EoT or Early Termination) visit following the directions described 
in Section 7.10.1. Skin biopsies should be performed at a site without scratch marks and at least 
2 cm apart. 
Skin punch biopsies must be performed by trained staff under local anaesthesia using a 
disposable 4-mm puncher. The puncher is pushed into the skin by rotary movement until a “give 
away” feel is perceived. Suture is generally not needed. A cotton bandage is sufficient 
(Nischal 2008).  
The skin biopsy specimens will be stored for relevant analyses of biomarkers of CKD-aP. The 
samples will be destructed within 1 year after trial completion. 
7.11.2 
Skin tape strips 
Skin tape strips will be obtained by a physician at Baseline and Week 12 or Early Termination in 
all subjects.  
Tape strips will be taken from the lower right quadrant at the Baseline visit and from the lower 
left quadrant at the Week 12 (EoT or Early Termination) visit following the directions described 
in Section 7.10.1.  
Tape stripping is a minimally invasive technique to sequentially remove stratum corneum by 
repeated application of appropriate adhesive tape. Areas with, e.g., eczema and scratch marks 
should be avoided. Round adhesive tape discs are attached to the skin for 10 seconds using a disc 
pressure applicator. The tapes are gently removed with a tweezer and stored in closed plastic 
vials at room temperature at the site and during shipment. At the central laboratory the samples 
must be stored between -20°C and -30°C until analysis. The first strip is discarded, and the 
following are stored together in groups as follows: strips 2-4, strips 5-7, and strips 8-10 (Kezic 
2011).   
The skin tape strips will be stored for relevant analyses of biomarkers of CKD-aP. The samples 
will be destructed within 1 year after trial completion. 
 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 49 - 
7.12 
Adverse events 
7.12.1 
Adverse events assessments 
The investigator or designee is responsible for obtaining, assessing, and documenting all AEs 
during the trial.  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered an investigational or non-investigational medicinal product and which does not 
necessarily have to have a causal relationship with this treatment. An AE can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. 
All AEs will be documented in the eCRF, including a description of each AE, AE relationship to 
IMP administration, start and stop dates, seriousness, severity, action taken and outcome.  
Any AE that meets the serious criteria must be reported as an SAE to PharmaLex (PLX) within 
24 hours of first awareness.  
Contact information:  
Company: PharmaLex A/S, Agern Allé 24, DK-2970 Hørsholm, Denmark 
E-mail: PV-nordic@pharmalex.com 
Throughout the trial, the occurrence of AEs should be monitored by nondirective questioning of 
the subject at each visit. Information on AEs can also be obtained from signs and symptoms 
detected during examinations, observations made by the trial site personnel, or spontaneous 
reports from subjects. Pre-existing conditions that worsen during the trial should also be recorded 
as AEs. This will also include worsening of the disease as judged by the investigator. 
AEs requiring therapy must be treated in accordance with recognised standards of medical care 
to protect the health and well-being of the subject. Treatment due to an AE will be recorded in 
the subject’s records and on the appropriate eCRF. 
7.12.2 
Reporting of adverse events 
Adverse event information will be collected from individual trial subjects from signature of the 
informed consent form until the last trial visit.  
If the event is reported as an SAE, the timelines for SAE reporting apply (see Section 7.12.10). If 
the event is reported as non-serious AE, it should be reported on the appropriate eCRF page.  
All SAEs and related non-serious AEs must be followed by the investigator until they are 
resolved or until judged by the investigator to be stable/needing no further follow-up. All 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 50 - 
relevant follow-up information will be reported in the eCRF (and to PharmaLex if it qualifies as 
an SAE, see Section 7.12.1). 
7.12.3 
Severity of adverse events 
The investigator is to classify the severity (intensity) of an AE according to the following 
definitions: 
• Mild – The subject was aware of the signs and symptoms, but the signs and symptoms 
were easily tolerated and does not interfere with daily activity. 
• Moderate – The signs and symptoms were sufficient to restrict, but did not prevent, usual 
daily activity for the subject. The subject is still able to function. 
• Severe – The subject was unable to perform usual daily activities. 
The maximum severity recorded during the course of an AE (mild, moderate, or severe) will be 
considered the final severity. 
7.12.4 
Relationship of adverse events to trial treatment  
The investigator is responsible for assessing the relationship of an AE to the IMP treatment using 
good clinical judgment and the following definitions: 
• Not related – The AE is clearly explained by another cause not related to the IMP 
administration; the temporal relationship of the AE to IMP administration makes a causal 
relationship clearly improbable or concomitant medication, therapeutics interventions, or 
underlying condition provide a sufficient explanation for the observed AE. 
• Unlikely related – The AE is most likely related to aetiology other than the IMP 
administration; the temporal relationship of the AE to IMP administration makes a causal 
relationship unlikely, and other concomitant medication, therapeutic interventions or 
underlying disease provide plausible explanations for the observed AE. 
• Possibly related – The AE and administration of IMP are temporally related, but the AE 
can be explained equally well by causes other than the IMP administration. A causal 
relationship is conceivable and cannot be dismissed. 
• Probably related – The AE and use of IMP are temporally related, and the AE is more 
likely explained by IMP administration than by other causes. Good reason and sufficient 
documentation to assume a causal relationship. 
The last relationship recorded during the course of an AE will be considered the final relationship 
as the investigator is assumed to have had the most information to perform the relationship 
assessment at that time. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 51 - 
7.12.5 
Outcome of adverse event 
The outcome of an AE will be classified as:  
• Recovered/resolved 
• Recovered/resolved with sequelae (note: in case of sequelae, the sequelae must be 
reported in eCRF) 
• Recovering/resolving 
• Not recovered/not resolved 
• Fatal 
• Unknown 
7.12.6 
Unexpected serious adverse events 
All SAEs will be assessed for expectedness by the sponsor or designee. An SAE is considered 
“unexpected” if its nature or severity is not included in the “Reference safety information” 
section in the MC2-25 cream IB. 
7.12.7 
Trial medication overdose 
An overdose of the IMP is a dose that is higher than the highest dose under clinical investigation.  
In the event of a clinically significant overdose, as judged by the investigator, the event should 
be reported as an AE and supportive treatment or discontinuation of the IMP may be applied as 
judged by the investigator. In view of the >40-fold systemic safety margin (see Section 2.3), the 
administered dose may be several fold higher than the highest dose under clinical investigation 
without necessarily qualifying as a clinically significant overdose.  
7.12.8 
Pregnancy 
Any pregnancy occurring from date of the informed consent signature until trial completion --
must be recorded in the eCRF and reported to PharmaLex as soon as it becomes known to the 
investigator and not later than within 24 hours of his/her knowledge of the occurrence of the 
pregnancy (see Section 7.12.10).  
The investigator must actively follow-up, document, and report to PharmaLex the progress of the 
pregnancy until outcome is reached.   
7.12.9 
Serious adverse event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death 
• Is life-threatening 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 52 - 
• Requires in-patient hospitalisation or prolongation of existing hospitalisation 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
• Other serious or important medical event  
Any medical important events that may not result in death, be life-threatening, or require 
hospitalisation may be considered an SAE when, based on appropriate medical judgment, they 
may jeopardise the subject or the subject may require medical or surgical intervention to prevent 
one of the outcomes listed in the above definitions.  
The death of a subject enrolled in a trial is per se not an event, but an outcome. Any event 
resulting in a fatal outcome must be fully documented and reported, regardless of the causality 
relationship to the IMP. 
Any pre-planned hospitalisations that are known at the time of signing the informed consent 
form will not be recorded as SAEs, however they will be recorded as AEs only.  
Any SAE, whether or not deemed IMP-related or expected, must be reported immediately to 
PharmaLex as soon as it becomes known to the investigator and not later than within 24 hours of 
his/her knowledge of the occurrence of an SAE (see Section 7.12.10). The investigator will 
document such events in the best possible detail on the SAE Report Form.  
A suspected unexpected serious adverse reaction (SUSAR) is an SAE that is both unexpected 
(not listed in the Reference Safety Information (RSI) section of the IB, and for which there is 
evidence to suggest a causal relationship between the drug and the SAE. The Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC) will be informed of SUSARs 
according to local requirements. All investigators participating in the trial will also be notified of 
SUSARs.  
Investigator instructions for reporting SAEs are provided in Section 7.12.10. 
SAEs occurring after a subject has completed the trial and deemed IMP-related by the 
investigator should be reported to the sponsor if the investigator becomes aware of them.  
 
7.12.10 
Reporting of serious adverse events and pregnancies 
7.12.10.1 
Contact person(s) and number(s) 
SAEs and pregnancies must be reported immediately (i.e., not later than 24 hours after first 
knowledge). The SAE or pregnancy report should be e-mailed or faxed to PharmaLex using the 
following e-mail or fax-number:  
                                        Email: PV-nordic@pharmalex.com 
                                        Fax number: +45 74 44 19 37 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 53 - 
 
7.12.10.2 
Reporting procedures 
Serious adverse events 
For each SAE, the investigator will complete a Serious Adverse Event Report Form and assess 
the relationship of each SAE to trial treatment. The completed form(s) should be sent to 
PharmaLex within 24 hours of first knowledge of the SAE.  
Follow-up reports regarding the status of the SAE and the subject’s subsequent course should be 
submitted until the SAE has resolved, is stabilised or needing no further follow-up (in the case of 
persistent impairment) or the subject dies. The form and acknowledgment of receipt will be 
retained. Contacts for reporting SAEs, pregnancies and other safety concerns are provided to 
each site.  
7.13 
COVID-19 Considerations 
COVID-19 control measures in different countries may impact the ability to adhere to some of 
the trial procedures described in this protocol. Due to challenges that include, but are not limited 
to, subject preferences, site closures, travel restrictions, and quarantines, some modifications to 
trial conduct during the COVID-19 pandemic may be necessary to ensure trial continuity. The 
following are allowable, as necessary, modifications to trial conduct during the COVID-19 
pandemic.  
• 
Prior to a trial visit at the site, the subject may be contacted and may be asked to be 
screened for potential exposure or infection to COVID-19 per local requirements. If 
the subject is suspected or known to be infected with COVID-19, the on-site visit may 
either be re-scheduled or a virtual visit may be performed instead, as applicable.  
• 
If a subject cannot attend the regularly scheduled trial visits in person due to 
COVID-19 necessitating a limit on in-person contact, the investigator may perform 
safety and efficacy assessments by phone or video to the extent possible. The 
investigator may use technology platforms that are considered suitable by the site.  
• 
Source documentation and the eCRF should note that the visit was performed virtually 
(not face-to-face). If certain trial procedures or assessments cannot be completed per 
the SoA, the reason for the missed assessment must be noted in the source 
documentation (e.g., COVID-19) and captured in the protocol deviations 
documentation. 
A detailed assessment of COVID-19-related risk and mitigation measures will be documented in 
the appropriate trial plans, e.g., trial risk management plan. 
Subjects who missed significant WI-NRS assessments due to COVID-19 may be replaced if the 
total number exceeds 10% of subjects enrolled. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 54 - 
8.0 
STATISTICAL AND ANALYTICAL PLANS AND DETERMINATION OF 
SAMPLE SIZE  
8.1 
General considerations for data analysis 
The methodology presented below represents a brief overview of the statistical methods that will 
be fully detailed in the statistical analysis plan (SAP). The SAP will be finalised before the 
database is locked. Any changes to the methods described in the final SAP will be described and 
justified in the clinical trial report. All statistical analyses will be performed using SAS statistical 
software (Version 9.4 or higher).  
Statistical significance will be tested at the two-sided 5% level unless otherwise specified. 
Superiority is concluded if a p-value of statistical hypothesis testing is below the level and the 
estimate of treatment difference is in favourable direction for MC2-25 cream.  
Categorical variables will be described by summary tables of frequencies (counts and 
percentages) per treatment group, continuous parameters by displaying arithmetic mean, median, 
minimum and maximum values, standard deviation, and, where applicable, 1st and 3rd quartiles. 
All collected and derived data will be presented in individual subject data listings. 
8.2 
Sample size and power considerations 
Approximately 108 subjects will be randomized in the trial in 2:1 ratio of MC2-25 cream to 
MC2-25 vehicle, including an assumption of 10% dropouts. For a two-sided test with a 5% level 
of significance (expected d=1.5 and s=2.46, d/s=0.61) this sample size will provide adequate 
power (≥80%) to compare mean change in WI-NRS from Baseline to Week 12 between MC2-25 
cream and MC2-25 vehicle with 72 and 36 subjects (Spencer 2018). 
8.3 
Analysis populations 
The analysis populations are defined as follows:  
Screened set (SS): all subjects who sign the informed consent form. 
Safety analysis set (SAS): all subjects who are randomized and dispensed the trial medication at 
Randomisation/Day 0, excluding subjects to whom trial medication is not dispensed or who 
return all of the trial medication unused. Subjects will be analysed according to the actual 
treatment. 
Full analysis set (FAS): all subjects who are randomized. Subjects will be analysed according to 
the randomized treatment.  
Modified full analysis set (MFAS): all subjects who are randomized and returned for at least 
one post-baseline scheduled visit with data on WI-NRS. Subjects will be analysed according to 
the randomized treatment. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 55 - 
Per-protocol set (PPS): a subset of the MFAS subjects who completed the trial with WI-NRS 
data for Week 12 and are deemed to have no important protocol deviations that could interfere 
with the objectives of this trial. Important deviations of eligibility criteria and other deviations 
from the protocol will be assessed. Important deviations from the protocol may lead to exclusion 
of a subject or data points from the PPS, which could have interfered with the administration of 
the treatment or the evaluation of treatment effect. All such decisions will be identified and 
documented before the final trial database is unblinded. Important protocol deviations may 
include, but are not limited to, medication non-compliance, missing consecutive application 
days, and intake of prohibited concomitant therapies, which may have an impact on the primary 
endpoint. 
The SAS will be used for all safety analyses. FAS, MFAS, and PPS will be used for efficacy 
analyses. 
8.4 
Background and demographic characteristics 
For the FAS (and MFAS if it differs from the FAS) and the SAS, summary tables will describe 
the trial population by treatment group and overall, with regard to demographic and other 
baseline characteristics. Demographics include age, sex, race, and ethnicity (Section 7.2). 
Baseline characteristics include medical history, CKD stage and duration, whether subjects are 
on dialysis or not and time since initiation of dialysis, weekly mean WI-NRS, time since start of 
CKD-aP, and selected laboratory parameters.   
8.5 
Trial medication/exposure 
Descriptive statistics will be used to summarise trial medication exposure for the SAS. Measures 
of IMP exposure will include the total duration of treatment, the total weight of trial medication 
used, the average weight of trial medication used and the total number of applications.   
8.6 
Prior and concomitant therapies 
For the SAS, prior and concomitant therapies (as defined in Section 6.7) will be summarized by 
treatment. Separate summaries will be given for prior therapies, for prior therapies ongoing at 
baseline, and for concomitant therapies. 
8.7 
Analysis of safety 
On the SAS, safety will be analysed by means of incidences of AEs, abnormalities in laboratory 
values, vital signs, physical examination and ECG findings. In addition, laboratory values will 
also be presented as described for continuous variables in Section 8.1. 
8.7.1 
Adverse events 
Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
terminology. Treatment-emergent adverse events (TEAEs), related TEAEs, non-serious TEAEs, 
serious TEAEs, related serious TEAEs, TEAEs leading to treatment discontinuation and Deaths 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 56 - 
will be summarised by the overall incidence of at least one event, incidence by body system, and 
incidence by body system and preferred term. Each subject will contribute only once (e.g., the 
first occurrence) to each of the rates, regardless of the number of occurrences (events) the subject 
experiences. The number of occurrences will also be displayed.  
Treatment-emergent AEs will be summarised by severity (mild, moderate, or severe), and by 
relationship to trial product (not related, unlikely, possibly, or probably). In summaries of 
severity and relationship, subjects who report more than one event that are mapped to the same 
preferred term will be counted only once under the strongest severity and relationship, 
accordingly. An AE is treatment-emergent if its date of onset is on or after the day of start of trial 
medication. An AE is related if relationship to trial product is not assessed as unrelated. 
8.8 
Analysis of efficacy 
On the FAS, all efficacy endpoints will be analysed, the primary endpoint also on the MFAS and 
the PPS. All endpoints, including PROs and HRQoL questionnaires, will be summarized as 
observed. For statistical analyses of primary and secondary endpoints, missing values will be 
imputed by different approaches described below. Further details will be given in the SAP.  
8.8.1 
Primary endpoint 
The primary endpoint, mean change in weekly mean WI-NRS recorded in the subject’s diary 
from Baseline to Week 12 for MC2-25 cream compared to MC2-25 vehicle, will be analysed by 
a mixed model of repeated measures with Baseline weekly mean WI-NRS as covariate and 
treatment, CKD stage stratum at baseline, systemic CKP-aP treatment status at baseline and visit 
as fixed factors with a two-sided α=0.05. The weekly mean WI-NRS is calculated as the average 
of minimum 4 WI-NRS values recorded once daily in the subject’s diary from 7 days prior to 
and including the visit days (i.e., must be recorded for 8 days total).  
On the FAS, the primary analysis and one sensitivity analysis will follow a treatment policy 
strategy irrespective of any potential intercurrent events. On primary analysis, missing values 
will be replaced following a multiple imputation procedure adequate for the endpoint assuming 
missingness appearing at random and based on 20 imputations. On the FAS, sensitivity analyses 
will include imputation by last observation carried forward (LOCF; treatment policy strategy) 
and multiple imputation of missing data and all data after start of rescue medication (hypothetical 
strategy). 
Applying the same statistical model, further estimands include multiple imputation on the MFAS 
and as observed on the PPS, both following a treatment policy strategy. If deaths occur, further 
estimands may be defined following a composite endpoint strategy.  
Supportive subgroup analyses will be conducted by dialysis status and CKD stages and by 
country on the FAS. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 57 - 
8.8.2 
Secondary endpoints 
Due to the phase 2 type of the trial, no alpha adjustment will be carried out for secondary 
endpoints. 
 For the FAS, secondary endpoints will be analysed as derived from the WI-NRS data by 
multiple imputation. A general estimating equations model applies with baseline weekly mean 
WI-NRS as covariate and treatment, dialysis status at baseline, systemic CKD-aP treatment 
status at baseline and visit as fixed factors with a two-sided α=0.05. Derived secondary endpoints 
are the rates of subjects with 4-point improvement, with 3-point improvement and with complete 
response in weekly mean WI-NRS, respectively. Complete response is given if scores equal 0 or 
1 in ≥80% of the non-missing WI-NRS values recorded in the subject’s diary 7 days prior to and 
including the post-baseline visit. 
9.0 
CHANGES IN THE PLANNED TRIAL 
9.1 
Protocol amendments 
Except for administrative changes, any changes or additions to this clinical trial protocol require 
a written protocol amendment that must be approved by the IRB/IEC, and if applicable the 
regulatory authorities, before implementation.  
These requirements for approval should in no way prevent any immediate action from being 
taken by the investigator or MC2 in the interests of preserving the safety of all subjects included 
in the trial. If an immediate change to the protocol is felt to be necessary by the investigator and 
is implemented for safety reasons, MC2 or designee should be notified, and the IRB/IEC should 
be informed according to their reporting requirements. 
9.2 
Completion, Termination or suspension of the trial 
The trial will be considered completed when the last subject has completed the last visit. Trial 
completion must be distinguished from premature termination of the trial and temporary 
suspension of the trial.  
The sponsor (MC2 Therapeutics) reserves the right to prematurely terminate or temporarily 
suspend trial sites or the trial at any time for any reason. The sponsor may terminate one or 
several sites/investigators at any time, provided there is reasonable cause and sufficient notice is 
given in advance of the intended termination.  
Reasons for the early termination of a trial site or the trial by the sponsor or investigator may 
include but are not limited to: 
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of subjects by the investigator 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 58 - 
• Discontinuation of further IMP development 
If the trial is prematurely terminated or suspended, the sponsor (or designee) shall promptly 
inform the investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) (CRO) used in the trial of the reason(s) for termination or suspension, as 
specified by the applicable regulatory requirements. The investigator shall promptly inform the 
subjects and should assure appropriate subject therapy and/or follow-up. 
10.0 
DATA HANDLING AND RECORD KEEPING 
10.1 
Recording of data 
Data handling and record keeping will be performed in compliance with the requirements of 
Articles 33 and 34 in conjunction with Article 28 (3) sentence 3 (EU) 2016/679 with its related 
local laws. 
All parties involved in this clinical trial will be obliged by law, as well as the established 
Standard Contractual Clauses (SCCs) to processing of any personalized data within the 
framework of this clinical trial in compliance with the EU GDPR and all related laws and 
regulations. The parties involved undertake to instruct and supervise their employees in regard to 
the requirements and compliance with EU GDPR with all related laws and regulations. 
At the sites, a very limited group of dedicated study team members have access to the subject 
source data: site staff, selected staff members of the CRO, authority representatives and the 
sponsor's auditors. Any subject personal and medical source data will be pseudonymized before 
leaving the sites. All subject personal and medical data are encrypted while at transfer, and 
appropriately protected at rest. 
The technical and organizational measures put in place by all parties result from the requirements 
of Articles 32 and 25 of the EU GDPR and form the minimal standard that all involved parties 
will comply with. For this purpose, the respective technical-operational measures (TOMs) of the 
parties involved are attached to their respective SCCs. The TOMs will have to address all aspects 
of data security, i.e.:  
(a) the pseudonymisation and encryption of personal data 
(b) the ability to ensure the ongoing confidentiality, integrity, availability and resilience of 
processing systems and services 
(c) the ability to restore the availability and access to personal data in a timely manner in the 
event of a physical or technical incident 
(d) a process for regularly testing, assessing and evaluating the effectiveness of technical and 
organisational measures for ensuring the security of the processing 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 59 - 
If one of the parties involved deviates or observes a deviation from these data security 
regulations, a notification to the sponsor's data protection officer will be made in accordance 
with the requirements of Articles 33 and 34 in conjunction with Article 28 (3) sentence 3 (EU) 
2016/679. The latter shall carry out an assessment of the situation in accordance with those 
articles and shall report to the competent supervisory authority and, if and when appropriate, to 
the subjects concerned, within the time limit set out therein. The measures to be taken depend on 
the seriousness of the deviation and the situation and shall be coordinated with the competent 
authority. Typically measures include at least an overall assessment of the magnitude of the data 
breach, the risk for involved data subjects (one or several), an impact assessment, as well as 
measures for correction of the actual occurrence and future prevention.  
10.1.1 
Source documents 
Source data are all the information in original records and copies of original records of clinical 
findings, observations, or other activities in the trial that are necessary for the reconstruction and 
evaluation of the trial.  
Trial data collection procedures must ensure that each data element can be traced with a high 
level of confidence from its originator or recorder to its representation in the trial database and 
then to its place in the analysis and report of trial results. Once recorded, the trial data must be 
protected from unauthorised modification or deletion, and all authorised modifications and 
deletions must be securely linked in the permanent record with their author, time of change, and 
reason for change (i.e., the audit trail must be maintained). Applicable data protection regulations 
must be followed to protect the privacy of trial subjects. 
The investigator will permit trial-related monitoring, audit(s), IRB/IEC review(s) and regulatory 
inspection(s), with direct access to all the required source records. 
The Principal Investigator will certify the trial data to be accurate and complete and will release 
the trial data for transmittal to MC2 or designee. 
Source records need to be preserved for the minimum period of time permitted by local 
regulations (see Section 10.2). For each subject enrolled, the investigator will indicate in the 
source record(s) that the subject participated in the trial. 
10.1.2 
Case report forms 
The primary data collection tool for the trial is an eCRF designed specifically for the trial. For 
each subject enrolled in the trial, an eCRF will be completed by the trial coordinator and signed 
by the investigator or his/her designate. Data recorded on source documents and required to be 
captured in the database will be entered in the eCRFs using a validated a 21 CFR Part 11-
compliant electronic data capture (EDC) system.  


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 60 - 
The investigator will be responsible for ensuring the accuracy of all data entered in the eCRFs. 
All eCRFs are to be completed in a timely manner. 
Errors occurring in the eCRFs will be queried. Queries raised by data reviewers must be 
addressed by site personnel. 
On request, the investigator will provide MC2 with additional data relating to the trial, or copies 
of relevant source records, duly anonymized (i.e., subject’s name is redacted). 
10.2 
Retention of documents 
The investigator shall take responsibility for maintaining adequate and accurate source 
documents of all observations and data generated during this trial, including any data 
clarification forms received from MC2 or designee. Such documentation is subject to inspection 
by the sponsor or its agents, the European Medicines Agency (EMA), and/or other regulatory 
agencies. The investigator is responsible for retention of essential documents including the 
Investigator Trial File for 25 years in accordance with the Clinical Trials Regulation (Regulation 
(EU) No 536/2014).  
11.0 
QUALITY CONTROL AND QUALITY ASSURANCE 
11.1 
Direct Access to source documents 
As specified in the investigator’s agreement, the investigator agrees to allow trial-related 
monitoring, audit(s), IRB/IEC review(s) and regulatory inspection(s), with direct access to all the 
required source records, and to allocate his/her time and the time of his/her staff to the 
auditor/inspector to discuss findings and any issues.  
11.2 
Monitoring procedures 
The Clinical Trial Monitor will contact and/or visit the investigator site periodically to verify the 
adherence to the protocol, the maintenance of trial-related source records, and the completeness 
and accuracy of all eCRF entries compared to source data. The investigator will cooperate with 
the trial monitor to ensure that any discrepancies that may be identified are resolved. 
11.3 
Audit and inspection 
The investigator will make all the trial-related source data and records available to a quality 
assurance auditor mandated by the sponsor, or to domestic or foreign regulatory inspectors, after 
reasonable notice. The main purposes of an audit or inspection are to confirm that the rights and 
well-being of the subjects have been adequately protected, and that all data relevant for the 
evaluation of the IP have been processed and reported in compliance with GCP/ICH and 
applicable regulatory requirements. 
The investigator is to notify the MC2 or designee immediately of any inspection by regulatory 
authorities or IRBs. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 61 - 
12.0 
ETHICS 
12.1 
Ethical conduct of the trial 
This trial must be carried out in compliance with the protocol and the applicable laws and 
regulatory requirements of the appropriate regulatory agency. The trial must be conducted in 
accordance with the ethical principles originating from the Declaration of Helsinki and 
amendments, Regulation [EU] No 536/2014 and applicable ICH-GCP guidelines. 
12.2 
Institutional review board (IRB) or independent ethics committee (IEC) 
This protocol, the proposed informed consent form, and other information for subjects must be 
reviewed and approved by an IRB or IEC, before the start of the trial, in compliance with local 
regulations. This committee must also approve any amendments to the protocol, other than 
administrative ones, before initiation of the amendment procedures. 
12.3 
Subject information and consent 
Before participation in the trial, each subject or guardian is required to provide written consent to 
participate in the trial. No trial-specific procedures will be performed before a subject’s informed 
consent is obtained.  
12.4 
Disclosure and confidentiality 
12.4.1 
Confidentiality of trial documentation 
By signing the protocol, the investigator agrees to keep all information provided by the sponsor 
in strict confidence and to request similar confidentiality from his/her staff and the IRB/IEC. 
Trial documents provided by the trial sponsor (i.e., protocols, Investigators’ Brochures, eCRFs 
and other material) will be stored appropriately to ensure their confidentiality. The information 
provided by the sponsor to the investigator may not be disclosed to others without direct written 
authorisation from the sponsor, except to the extent necessary to obtain informed consent from 
subjects who wish to participate in the trial. 
12.4.2 
Privacy of individual health information  
The investigator will undertake to protect the privacy of all individually identifiable health 
information and personalized information as specifically agreed to by each individual subject 
through the written informed consent as per the applicable data protection rules in each of the 
countries, where the study is conducted. The Informed Consent document will include a request 
of the subject’s consent to release the collected data for research purposes in such a way that the 
individual’s identity remains masked for the specified purposes, the specified duration, by the 
specified parties and at the specified locations. While all data records will be identified by the 
corresponding subject number, the identity of the subject will be held in confidential source 
documents at the trial site. All trial personnel with access to this information are legally bound 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 62 - 
not to disclose such information. The sponsor and all involved parties will comply with the 
respective data protection rules, which are applicable individually. 
12.5 
Subject involvement in the design of the clinical trial 
Facilitated by Kidney Research UK (KRUK), a panel including nephrologists, dermatologists, 
and 8 patients with CKD-aP were given the opportunity to review and provide comments on the 
protocol before finalization. 
13.0 
EMERGENCY PROCEDURES 
13.1 
Emergency unblinding  
The IWR system will be programmed with blind-breaking instructions. In case of an emergency, 
the investigator has the sole responsibility for determining if unblinding of a subject’s 
intervention assignment is warranted. Subject safety must always be the first consideration in 
making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact the sponsor prior to unblinding a subject’s 
intervention assignment unless this could delay emergency treatment of the subject. If a subject’s 
intervention assignment is unblinded, the sponsor must be notified within 24 hours after breaking 
the blind. The date and reason that the blind was broken must be recorded in the source 
documentation and case report form, as applicable. 
14.0 
INSURANCE 
MC2 has taken out appropriate insurance policies covering the subjects in the clinical trial in 
accordance with applicable laws and regulations. 
15.0 
PUBLICATION POLICY 
The clinical trial will be registered and results will be posted on www.clinical trial.gov and 
EudraCT in accordance with applicable local regulations.  
All publications (e.g., manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this trial must be submitted to MC2 for review, as specified in the Clinical Trial Agreement 
between the institution, investigator and MC2 or its designee. 
16.0 
REFERENCES 
Adamolekun B. Neurological disorders associated with cassava diet: a review of putative 
etiological mechanisms. Metab Brain Dis. 2011;26(1):79-85.  
Baker LB, Wolfe AS. Physiological mechanisms determining eccrine sweat composition. Eur J 
Appl Physiol. 2020;120(4):719-752.  


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 63 - 
Collaboration, Chronic Kidney Disease. 2020. 'Global, regional, and national burden of chronic 
kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017', 
Lancet, 395: 709-33. 
Dipeptiven® Summary of Product Characteristics (SmPC) 2015. 
Finlay AY. Defining the fingertip unit. BMJ. 2012;344:e3061 
Finlay AY, Edwards PH, Harding KG. “Fingertip unit” in dermatology. Lancet. 
1989;2(8655):155. 
Gorisse L, Pietrement C, Vuiblet V, et al. Protein carbamylation is a hallmark of aging. Proc Natl 
Acad Sci U S A. 2016;113(5):1191-6. 
Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney 
disease. Cochrane Database Syst Rev. 2020;12(12):CD011393. 
Hill, Nathan R., Samuel T. Fatoba, Jason L. Oke, Jennifer A. Hirst, Christopher A. O'Callaghan, 
Daniel S. Lasserson, and F. D. Richard Hobbs. 2016. 'Global Prevalence of Chronic Kidney 
Disease - A Systematic Review and Meta-Analysis', PLoS ONE, 11: e0158765-e65. 
Jaisson S, Pietrement C, Gillery P. Protein carbamylation: chemistry, pathophysiological 
involvement, and biomarkers. Adv Clin Chem. 2018;84:1-38. 
Jaisson S, Lorimier S, Ricard-Blum S, et al. Impact of carbamylation on type I collagen 
conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem 
Biol. 2006;13(2):149-59. 
Johansson O, Hilliges M, Ståhle-Bäckdahl M. Intraepidermal neuron-specific enolase (NSE)-
immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance 
hemodialysis. Neurosci Lett. 1989;99(3):281-6. 
Kezic S, O’Regan GM, Yau N, Sandilands A, Chen H, Campbell LE, et al. Levels of filaggrin 
degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. 
Allergy. 2011;66(7):934-40. 
Kimani S, Moterroso V, Morales P. Cross-species and tissue variations in cyanide detoxification 
rates in rodents and non-human primates on protein-restricted diet. Food Chem Toxicol. 
2014;66:203-9. 
Kopple JD. Abnormal amino acid and protein metabolism in uremia. Kidney Int. 
1978;14(4):340-8.  
Korsuva™ United States Package Insert (USPI). Stamford, CT: Cara Therapeutics, Inc; 2021. 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 64 - 
Kraus LM, Jones MR, Kraus AP. Essential carbamoyl-amino acids formed in vivo in patients 
with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, 
identification, and quantitation. J Lab Clin Med. 1998;131(5):425-31. 
Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int 
Suppl. 2001;78:S102-7. 
Martin CE, Clotet-Freixas S, Farragher JF, et al. Have we just scratched the surface? A narrative 
review of uremic pruritus in 2020. Can J Kidney Health Dis. 2020;7:2054358120954024.  
Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in 
hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1410-9. 
(Nalfurafine Report) Evaluation and Licensing Division, Pharmaceutical and Food Safety 
Bureau, Ministry of Health, Labour and Welfare (Japan). Report on the Deliberation Results. 
06 November 2008. 
Nischal U, Nischal Kc, Khopkar U. Techniques of skin biopsy and practical considerations. 
J Cutan Aesthet Surg. 2008;1(2):107-11. 
Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: international results 
from the Dialysis Outcomes and Practice Patterns Study (DOPPS) Nephrol Dial Transplant. 
2006;21(12):3495-505.  
Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and 
treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12(12):2000-7. 
Sacco JJ, Botten J, Macbeth F. The average body surface area of adult cancer patients in the UK: 
a multicentre retrospective study. PLoS One. 2010;5(1):e8933.  
Shirazian S, Aina O, Park Y, et al. Chronic kidney disease-associated pruritus: impact on quality 
of life and current management challenges. Int J Nephrol Renovasc Dis. 2017;10:11-26. 
Spencer. 2018. Clinically meaningful itch reduction by CR845. Poster 
Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, 
and patient-reported outcomes in hemodialysis patients. Kidney Med. 2021;3(1):42-53 e1.  
Sukul N, Speyer E, Tu C, et al. Pruritus and patient reported outcomes in non-dialysis CKD. Clin 
J Am Soc Nephrol. 2019;14(5):673-81. 
Thomas CL, Finlay AY. The “handprint” approximates to 1% of the total body surface area 
whereas the “palm minus the fingers” does not. Br J Dermatol. 2007;157(5):1080-1.  


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 65 - 
Vychytil A, Herzog R, Probst P. A randomized controlled trial of alanyl-glutamine 
supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health. 
Kidney Int. 2018;94(6):1227-37. 
Yoshiike T, Aikawa Y, Sindhvananda J, et al. Skin barrier defect in atopic dermatitis: increased 
permeability of the stratum corneum using dimethyl sulfoxide and theophylline. J Dermatol Sci. 
1993;5(2):92-6. 
 
 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 66 - 
17.0 
APPENDICES 
 
17.1 
Appendix 1 
Contact list of MC2 and protocol authors  
Contact details for MC2 representatives are provided to the trial sites on a list outside of the 
protocol, which is included in the clinical trial application. The name and address of each third-
party vendor (e.g. clinical laboratory) used in this trial will be maintained in the investigator´s 
and sponsor´s files 
Sponsor 
MC2 Therapeutics Ltd  
James House, Emlyn Lane 
Leatherhead KT22 7EP 
United Kingdom 
 
Protocol Authors 
Maj Dinesen, Director Clinical Development MC2 Therapeutics 
Birgitte Vestbjerg, Senior Advisor Clinical Operations, MC2 Therapeutics 
Carsten Makus, Advisor Clinical Operations, SRE GmbH 
Frank Freischläger, Senior Advisor Biostatistics, Estimondo 
 
 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers.3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
- 67 - 
17.2 
Appendix 2 
Vendor overview  
 
Vendor 
Role 
SRE GmbH 
CRO 
Pharmalex 
Pharmacovigilance Provider 
 
 
 
 
 
 
 


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers. 3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
CLINICAL TRIAL PROTOCOL APPROVAL FORM 
 
Product: MC2-25 cream 
 
Protocol number: MC2-25-C1 
 
Protocol title: A Parallel-group (2-Arm), Randomized, Double-blind, 12 week Trial to Evaluate 
the Efficacy and Safety of MC2 25 Cream and MC2-25 Vehicle in Subjects with 
Chronic Kidney Disease-associated Pruritus (CKD aP) 
 
Version: 3.0_EU 
 
Date: 30-Nov-2022 
 
 
 
The following person has approved this clinical trial protocol: 
 
Maj Dinesen 
Head of Clinical Development 
MC2 Therapeutics 
 
 
Date and signature 
 
 
Maj 
Dinesen
Digitally signed by Maj Dinesen 
DN: cn=Maj Dinesen, o=MC2 
Therapeutics, ou=Director Clinical 
Development, 
email=mdi@mc2therapeutics.com, 
c=DK 
Date: 2022.11.30 13:21:02 +01'00'


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers. 3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
CLINICAL TRIAL PROTOCOL APPROVAL FORM 
 
Product: MC2-25 cream 
 
Protocol number: MC2-25-C1 
 
Protocol title: A Parallel-group (2-Arm), Randomized, Double-blind, 12 week Trial to Evaluate 
the Efficacy and Safety of MC2 25 Cream and MC2-25 Vehicle in Subjects with 
Chronic Kidney Disease-associated Pruritus (CKD aP) 
 
Version: 3.0_EU 
 
Date: 30 Nov 2022 
 
 
The following person has approved this clinical trial protocol: 
 
Frank Freischläger Senior Advisor 
Biostatistics Estimondo 
 
 
Date and signature 
 
 
Frank 
Freischläger
Digitally signed by Frank 
Freischläger 
Date: 2022.11.30 
13:38:13 +01'00'


Protocol No. MC2-25-C1 
Clinical Trial Protocol 
Vers. 3.0_EU/30-Nov-2022 
MC2 Therapeutics  
 
CLINICAL TRIAL PROTOCOL APPROVAL FORM 
 
Product: MC2-25 cream 
 
Protocol number: MC2-25-C1 
 
Protocol title: A Parallel-group (2-Arm), Randomized, Double-blind, 12 week Trial to Evaluate 
the Efficacy and Safety of MC2 25 Cream and MC2-25 Vehicle in Subjects with 
Chronic Kidney Disease-associated Pruritus (CKD aP) 
 
Version: 3.0_EU 
 
Date: 30 Nov 2022 
 
 
The following person has approved this clinical trial protocol: 
 
Irene Sandholdt 
Senior Advisor Clinical Operations 
MC2 Therapeutics 
 
 
Date and signature 
 
 
Irene 
Sandholdt
Digitally signed by Irene 
Sandholdt 
Date: 2022.11.30 13:32:36 
+01'00'

SAP_001.pdf: 
MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0  
Page 0 of 26 
 
STATISTICAL ANALYSIS PLAN 
 
MC2-25-C1 
 
Final V1.0  
18 SEP 2023 
 
A Parallel-group (2-Arm), Randomized, Double-blind, 12-week Trial to Evaluate the Efficacy 
and Safety of MC2-25 Cream and MC2-25 Vehicle in Subjects with Chronic Kidney Disease-
associated Pruritus (CKD-aP) 
 
MC2 Therapeutics Ltd. 
1A Guilford Business Park 
Guilford GU2 8XG 
United Kingdom 
 
 
Written By:    
 
 
______________________________ 
_____________________ 
Craig W. Wesselman  
 
 
Date 
Director of Statistics 
Symbio LLC 
 
 
 
Approved By:     
 
 
______________________________ 
____________________ 
Frank Freischläger  
Date 
Senior Advisor Biostatistics 
Estimondo GmbH 
 
 
______________________________ 
____________________ 
Maj Dinesen 
Date 
Head of Clinical Development 
MC2 Therapeutics Ltd. 
 
 
 
 
 
 
 
CONFIDENTIAL  
 
 
Frank Freischläger
Digitally signed by Frank Freischläger 
Date: 2023.09.19 09:56:54 +02'00'
Digitally signed by Maj Dinesen 
DN: cn=Maj Dinesen, o=MC2 Therapeutics, 
ou=Head of Clinical Development, 
email=mdi@mc2therapeutics.com, c=DK 
Date: 2023.09.19 10:48:32 +02'00' 
Adobe Acrobat version: 2023.006.20320
Craig W. Wesselman
Digitally signed by Craig W. 
Wesselman 
Date: 2023.09.19 12:23:06 -06'00'


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
1 
 
 
Table of Contents 
1 
Purpose of Statistical Analysis Plan ........................................................................................................ 4 
2 
Study Objectives ....................................................................................................................................... 4 
3 
Study Design ............................................................................................................................................. 4 
3.1 
Primary Efficacy Endpoint ............................................................................................................................ 7 
3.3 
Secondary Efficacy Endpoints ....................................................................................................................... 7 
3.4 
Other Efficacy Endpoints ............................................................................................................................... 7 
3.5 
Safety Endpoints ........................................................................................................................................... 14 
3.6 
Other Endpoints ............................................................................................................................................ 15 
4 
Analysis Populations .............................................................................................................................. 15 
5 
Planned Analyses .................................................................................................................................... 16 
5.1 
Methodological Considerations.................................................................................................................... 16 
5.2 
Handling of Dropouts or Missing Data ....................................................................................................... 17 
5.2.1 
Missing Data ............................................................................................................................................ 17 
5.2.2 
Missing Data Handling- A While-on-Treatment Strategy ....................................................................... 18 
5.2.3 
Analysis Windows ................................................................................................................................... 18 
5.2.4 
COVID-19 Impacted Visits ..................................................................................................................... 18 
5.3 
Demographics and Background Characteristics ........................................................................................ 18 
5.4 
Subject Accountability .................................................................................................................................. 19 
5.5 
Efficacy Analyses .......................................................................................................................................... 19 
5.5.1 
Primary Efficacy Analyses ...................................................................................................................... 19 
5.5.1.1 
Subgroup Analysis ................................................................................................................................... 19 
5.5.2 
Secondary Efficacy Analyses .................................................................................................................. 19 
5.5.3 
Other Efficacy Analyses .......................................................................................................................... 20 
5.6 
Other Safety Variables and Analyses .......................................................................................................... 20 
5.6.1 
Product Compliance ................................................................................................................................. 20 
5.6.2 
Drug Accountability and Extent of Exposure: ......................................................................................... 21 
5.6.3 
Prior and Concomitant Therapies/ Medications ....................................................................................... 21 
5.6.4 
Adverse Events ........................................................................................................................................ 21 
5.6.5 
Other Safety Endpoints ............................................................................................................................ 22 
6 
Appendices .............................................................................................................................................. 22 
6.1 
Handling of Missing or Incomplete Dates for Adverse Events , Prior and Concomitant Medications . 22 
6.2 
Changes in analyses from protocol: ............................................................................................................. 23 
6.3 
Reference Materials ...................................................................................................................................... 24 
6.3.1 
EQ-5D-5L Index Value ........................................................................................................................... 24 
6.3.2 
Systemic treatment CKD-aP can be identified via ATC code Level 3 or 4: ............................................ 25 
 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
2 
 
List of Abbreviations and Definitions of Terms 
 
Term 
Definition 
AE 
adverse event 
ATC 
anatomical therapeutic chemical 
BMI 
body mass index 
BSA 
body surface area 
CI 
confidence interval 
CGA 
clinician’s global assessment 
CKD-aP 
chronic kidney disease-associated pruritus 
COVID-19 
coronavirus disease of 2019 
CI 
confidence interval 
CSR 
clinical study report 
CTA 
clinician’s targeted assessment 
DBP 
diastolic blood pressure 
FAS 
full analysis set 
ECGs 
electrocardiograms 
EoT 
end of treatment 
ET 
early termination 
FU 
follow up 
g 
gram 
HR 
Heart rate 
IMP 
investigational medicinal product 
LC-MS/MS 
liquid chromatography–tandem mass spectrometry 
LOCF 
last-observation-carried-forward 
LS 
least squares 
MCMC 
markov chain monte carlo 
MedDRA 
medical dictionary for regulatory activities 
MFAS 
modified full analysis set 
MI 
multiple imputation 
MMRM 
mixed model of repeated measures 
NA 
not applicable 
PPS 
per-protocol set 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
3 
 
Term 
Definition 
PRO 
patient reported outcome 
PT 
preferred term 
Q1 
1st quartile 
Q3 
3rd quartile 
SAE 
serious adverse event 
SAS 
safety analysis set 
SAS® 
statistical analysis software (version 9.4 or higher) 
SAP 
statistical analysis plan 
SBP 
systolic blood pressure 
SD-NRS 
skin dryness numeric rating score 
SE 
standard errors 
SGIC 
subject’s global impression of change 
SI-NRS 
sleeploss due to itch numeric rating score 
SOC 
system organ class 
SS 
screened set 
TEAEs 
treatment-emergent adverse events 
temp 
body tempreture 
TESAEs 
treatment-emergent serious adverse events 
WHO-DD 
world health organization drug dictionary 
WI-NRS 
worst itch numeric rating score 
 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
4 
 
Statistical Analysis Plan 
 
1 
Purpose of Statistical Analysis Plan 
The purpose of the statistical analysis plan (SAP) is to describe in detail all the data, statistical 
methods, and summary tables required to implement the statistical analysis of MC2-25-C1 
(Section 8.0 in the study protocol version 3.0, dated 30 NOV 2022). 
This SAP will be finalized before the database lock for the final analysis. Any changes between 
the statistical methods provided in the clinical study protocol and this SAP will be explained 
herein; any changes or deviations from this SAP relative to the analyses performed will be fully 
documented in the clinical study report (CSR). Minor changes or deviations from the templates 
for tables, and listings need not be documented in the CSR. 
2 
Study Objectives 
The primary objective of this study is to explore the clinical efficacy of MC2-25 cream 
compared to MC2-25 vehicle in adults with chronic kidney disease-associated pruritus 
(CKD-aP). 
The secondary objective of this study is to explore the safety of MC2-25 cream compared to 
MC2-25 vehicle in adults with CKD-aP. 
Other objective of this study is to explore the subclinical effects of MC2-25 cream in adults with 
CKD-aP. 
3 
Study Design 
This is a multicentre, phase 2, randomized, double-blind, 2-arm, parallel-group, and vehicle-
controlled trial in subjects with CKD-aP. Approximately 108 eligible subjects will be 
randomized in a 2:1 ratio to MC2-25 cream or MC2-25 vehicle, respectively. Subjects will apply 
the assigned investigational medicinal product (IMP) twice daily for 12 weeks. 
Figure 1 : 
Study Design  
 
 
Subjects will be seen at the trial sites at Screening, Baseline, Week 1, Week 4, Week 8, and 
Week 12 (end of treatment, EoT). Subjects who have ongoing serious adverse events (SAEs) or 
related adverse events (AEs) at Week 12 will have a follow-up (FU) visit at Week 14 or (in case 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
5 
 
of early treatment discontinuation) 14 days after the EoT visit, whichever comes first. 
Additionally, phone contacts are planned at Week 2, Week 6, and Week 10. 
Table 1 
Schedule of Events 
Trial Period 
Screening 
Period 
Treatment Period 
FU 
period1 
Visit Number2 
1 
(Screening) 
2  
(Baseline) 
3 
4 
5 
6 
7 
8 
9 
(EoT)3  
10 
(FU) 
Trial Week 
 
0 
1 
2 
4 
6 
8 
10 
12 
14 
Days from Baseline (Visit 
2) 
Visit Window 
-28 to -1 
NA 
0 
NA 
7 
±1 
14 
±2 
28 
±4 
42 
±2 
56 
±4 
70 
±2 
84 
±4 
 
±2 
In-clinic or Phone Visits4 
In-Clinic 
In-Clinic 
In-
Clinic Phone 
In-
Clinic Phone 
In-
Clinic Phone 
In-
Clinic 
In-
Clinic 
Informed Consent5 
X 
 
 
 
 
 
 
 
 
 
Eligibility Assessment 
X 
X 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
CKD History 
X 
 
 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
 
CKD-aP Treatment 
History 
X 
 
 
 
 
 
 
 
 
 
Worst Itch NRS (WI-
NRS) – at-home (diary) 
assessments6 
 
X 
X 
 
X 
 
X 
 
X 
 
Worst Itch NRS (WI-
NRS) – On-site 
assessment7, 8 
X 
X 
X 
 
X 
 
X 
 
X 
 
Sleeploss due to Itch NRS 
(SI-NRS)8  
X 
X 
X 
 
X 
 
X 
 
X 
 
Skin Dryness NRS (SD-
NRS)8  
X 
X 
X 
 
X 
 
X 
 
X 
 
Subject’s Global 
Impression of Change 
(SGIC)8 
 
 
X 
 
X 
 
X 
 
X 
 
Subject´s rating of 
importance of 
improvement8 
 
 
X 
 
X 
 
X 
 
X 
 
Subject’s indication of 
CKD-aP treatment area 
size8, 9 
 
X 
X 
 
X 
 
X 
 
X 
 
5D-Itch8  
 
X 
 
 
X 
 
X 
 
X 
 
Skindex-108 
 
X 
 
 
X 
 
X 
 
X 
 
EQ-5D-5L8 
 
X 
 
 
X 
 
X 
 
X 
 
CKD-aP target area 
identification 
 
X 
 
 
 
 
 
 
 
 
CGA of Skin Appearance 
X 
X 
X 
 
X 
 
X 
 
X 
 
CTA of Skin Appearance 
 
X 
X 
 
X 
 
X 
 
X 
 
Physical examination10 
X 
X 
 
 
 
 
 
 
X 
(X) 
Vital signs11 
X 
X 
 
 
X 
 
X 
 
X 
(X) 
Single 12-lead ECG 
 
X 
 
 
X 
 
 
 
X 
(X) 
Pregnancy Testing12 
X 
X 
 
 
X 
 
 
 
X 
(X) 
Laboratory Assessments13 
X 
X 
 
 
X 
 
 
 
X 
(X) 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
6 
 
Trial Period 
Screening 
Period 
Treatment Period 
FU 
period1 
Visit Number2 
1 
(Screening) 
2  
(Baseline) 
3 
4 
5 
6 
7 
8 
9 
(EoT)3  
10 
(FU) 
Trial Week 
 
0 
1 
2 
4 
6 
8 
10 
12 
14 
Days from Baseline (Visit 
2) 
Visit Window 
-28 to -1 
NA 
0 
NA 
7 
±1 
14 
±2 
28 
±4 
42 
±2 
56 
±4 
70 
±2 
84 
±4 
 
±2 
Imaging of CKD-aP14 
 
X 
 
 
X 
 
 
 
X 
 
Randomisation 
 
X 
 
 
 
 
 
 
 
 
Diary (Handout) 
X 
X 
X 
 
X 
 
X 
 
 
 
Biopsy15 
 
X 
 
 
 
 
 
 
X 
 
Tape stripping16 
 
X 
 
 
 
 
 
 
X 
 
Prior & concomitant 
therapies17 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational medicinal 
product (IMP) 
dispensation 
 
X 
 
 
X 
 
X 
 
 
 
IMP return, compliance 
and accountability 
 
 
 
 
X 
 
X 
 
X 
 
IMP application18 
 
X 
 
Diary (Review) 
 
X 
X 
 
X 
 
X 
 
X 
 
1. Follow-up (FU) visit is only applicable if there are ongoing serious adverse events (SAEs) or related adverse events 
(AEs) at Week 12. (X) indicates assessments to be performed if judged necessary by the investigator. 
2. An unscheduled visit can be conducted to perform any of the postbaseline assessments or procedures included in the 
SoA if deemed necessary by the Investigator. 
3. In the case of trial withdrawal or treatment discontinuation, all assessments of the Week 12 (End of Treatment [EoT]) 
visit have to be performed. The end of treatment form must be completed when treatment is discontinued and the 
end of trial form must be completed at end of the trial or in case of trial withdrawal.  
4. Phone calls: To remind subjects about diary documentation (in particular once-daily WI-NRS assessments that must 
be performed for 8 days leading up to each on-site visit [i.e., from day -7 to day 0 where day 0 = next on-site visit 
day]) and to ask for AEs. Phone visits may be replaced by in-clinic visits where relevant, e.g., in subjects going to 
the dialysis unit for haemodialysis. 
5. Informed consent must be signed by both subject and investigator before any trial-related procedures are performed. 
6. At-home (diary) assessments must be performed for 8 days leading up to each visit, i.e., from day -7 to day 0 where 
day 0 = next on-site visit day. 
7. The WI-NRS must also be reported by the subject at on-site visits  
8. At all on-site visits, all patient-reported outcome (PRO) assessments should be completed before all other clinical 
assessments or procedures. 
9. The trial staff must estimate the % body surface area treated based on the subject’s indication of CKD-aP treatment 
area size on the CKD-aP treatment area diagram. 
10. Physical exam: A complete physical examination is required at Screening and Week 12 (EoT or Early Termination) 
visits. An abbreviated physical examination is required at the Baseline visit (and if judged necessary by the 
investigator) at the FU visit if the FU visit is applicable.  
11. Vital signs include blood pressure, heart rate, and body temperature measurement. For subjects on haemodialysis 
vital signs are to be assessed prior to dialysis. Blood pressure and pulse rate will be taken with the subject in the 
sitting position with approximately 5 minutes rest prior to measurement.  
12. Serum pregnancy tests are conducted for women of childbearing potential. At Baseline a urine pregnancy test must 
also be conducted except for dialysis subjects with anuria.  
13. For subjects on dialysis, the blood samples must be collected before dialysis.  


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
7 
 
14. Only at selected sites and only for subjects who have provided additional consent. CKD-aP target area selected at 
Baseline. Images of CKD-aP target area must be taken before tape stripping and skin biopsies. 
15. Only at selected sites and only for subjects who have provided additional consent. Biopsy: 4 mm skin punch biopsy 
(optional) is taken from the CKD-aP target area.  
16. Tape stripping is conducted in all subjects from the CKD-aP target area. 
17. “Therapies” refers to medications and therapies. 
18. The first IMP application shall preferably be performed in the clinic under surveillance, and assistance, if necessary, 
of trial staff. 
3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the mean change in weekly mean Worst Itch Numeric Rating 
Score (WI-NRS) recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream 
compared to MC2-25 vehicle. Weekly mean WI-NRS is calculated as the average of all and at 
least 4 non-missing WI-NRS values recorded in the subjects’ diaries for the 7 days prior to and 
including the scheduled in clinic visits (8 days in total expected). If less than 4 observations are 
recorded in the 8 days expected, the weekly mean WI-NRS will be considered missing.  
3.2 
Key Secondary Efficacy Endpoint 
The key secondary efficacy endpoint is to compare percentage of subjects obtaining a  4-point 
improvement in weekly mean WI-NRS recorded in the subjects’ diaries from Baseline to Week 
12 between MC2-25 cream and MC2-25 vehicle.  
3.3 
 Secondary Efficacy Endpoints 
The secondary efficacy endpoints will compare MC2-25 cream and MC2-25 vehicle for 
following points: 
- Percentage of subjects obtaining a  4-point improvement in weekly mean WI-NRS recorded 
in the subjects’ diaries from Baseline to Week 1, Week 4 and Week 8. 
- Percentage of subjects obtaining a  3-point improvement in weekly mean WI-NRS recorded 
in the subjects’ diaries from Baseline to Week 1, Week 4, Week 8 and Week 12. 
- Percentage of subjects obtaining a complete response in weekly WI-NRS recorded in the 
subjects’ diaries from Baseline to Week 1, Week 4, Week 8 and Week 12. Complete response 
is defined as scores equal to 0 or 1 in  80% of the non-missing WI-NRS values recorded in 
the subjects’ diaries 7 days prior to and including the scheduled in clinic visits. 
- Percentage of subjects obtaining an alternative complete response in weekly WI-NRS recorded 
in the subjects’ diaries from Baseline to Week 1, Week 4, Week 8 and Week 12. Alternative 
complete response is defined as scores equal to 0 or 1 in   70% of the non-missing WI-NRS 
values recorded in the subjects’ diaries 7 days prior to and including the scheduled in clinic 
visits.  
3.4 
Other Efficacy Endpoints 
Other endpoints compare MC2-25 cream and MC2-25 vehicle and are: 
- Mean change in WI-NRS recorded in the subject’s diary from Baseline to Week 1, Week 4, 
and Week 8. 
- Mean change in WI-NRS recorded during on-site visits from Baseline to Week 1, Week 4, 
Week 8 and Week 12. 
- Mean change in Sleeploss due to Itch Numeric Rating Score (SI-NRS) from Baseline to Week 
1, Week 4, Week 8 and Week 12. 
- Mean change in Skin Dryness Numeric Rating Score (SD-NRS) from Baseline to Week 1, 
Week 4, Week 8 and Week 12. 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
8 
 
Table 2 
WI-NRS, SI-NRS, SD-NRS scale and scores: 
Worst Itch/ Worst Sleep Loss/ Worst Skin Dryness in last 24 hours 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
No Itch/ 
No 
Sleeploss/ 
No Skin 
Dryness 
 
 
 
 
 
 
 
 
 
Worst 
Imaginable 
Itch/ 
Sleeploss/ 
Skin 
Dryness 
 
- Percentage of subjects who reported an improvement in Subject’s Global Impression of 
Change (SGIC) (i.e. “Very much better”, “Much better” or  “A little better")  will be reported 
for Week 1, Week 4, Week 8 and Week 12 for WI-NRS, SI-NRS and SD-NRS.  
Note: SGIC will be summarized for all subjects (see Table 3). Categories 1 to 3 will be 
summarized as combined “Improvement in SGIC score”. Categories 1 to 7 will be summarized 
individually. 
 
Table 3 
SGIC for itch, sleep loss and skin dryness. 
 
Choose response that best describes overall change in itch, sleep loss and skin dryness 
since you started taking the trial medication. 
Improvement 
in 
SGIC  
( 1 to 3) 
1 
Very much better 
2 
Much better 
3 
A little better 
 
4 
No change 
 
5 
A little worse 
 
6 
Much worse 
 
7 
Very much worse 
 
- Percentage of subjects who reported “an important improvement” in Subject’s rating of 
importance of improvement (i.e., subjects who respond “Yes” to Question 1 in the ‘Subjects 
rating of importance’ assessment) for WI, SI, and SD at Week 1, Week 4, Week 8, and Week 
12 or ET. 
 
- Mean change in Subject’s indication of CKD-aP treatment area size from Baseline to Week 4, 
Week 8 and Week 12. 
 
- Mean change in 5D-Itch (Domain Scores and Total Score) from Baseline to Week 4, Week 8 
and Week 12 
The 5D-Itch consists of 5 domains numbered 1-5.  
 Domains 1-3 are single item (question) domains exploring the Duration (Duration 
domain), Degree (Degree domain) and Direction (Direction domain) of Itch. For each 
of domains 1-3 the domain score is equal to the value indicated below the response 
choice (range 1–5). 
 Domain 4 (Disability domain) includes four items (questions) assessing the impact of 
itching on daily activities: sleep, leisure/social activities, housework/errands and 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
9 
 
work/school). For domain 4 the score is achieved by taking the highest score on any of 
the four items (range 1-5). 
 Domain 5 (Distribution domain) assesses the number of affected body parts out of 16 
possible options. For domain 5 the score is obtained by tallying the number of affected 
body parts and the sum is sorted into five scoring bins: sum of 0–2 = score of 1, sum of 
3–5 = score of 2, sum of 6–10 = score of 3, sum of 11-13 = score of 4, and sum of 14-
16 = score of 5 (range 1-5).  
 The total score is achieved by summing together the 5 domain scores and can therefore 
range between 5 (no pruritus) and 25 (most severe pruritus). 
 Continuous descriptive statistics will be provided for all individual domains except 
Domain 5 from Baseline to Week 4, Week 8 and Week 12.  
 Mean change in 5D-Itch Total Score will be presented using continuous descriptive 
statistics from Baseline to Week 4, Week 8 and Week 12. 
 
Table 4 
5D- Itch Questionnaire 
1. Duration 
During the last 2 weeks, how many hours a day have you been 
itching? 
 
Less than 
6hrs a day 
6-12hrs/ day 12-18hrs/ 
day 
18-23hrs/ 
day 
All day 
 
1 
2 
3 
4 
5 
2. Degree 
Please rate the intensity of your itching over the past 2 weeks 
 
Not 
Present 
Mild 
Moderate 
Severe 
Unbearabl
e 
 
1 
2 
3 
4 
5 
3. Direction 
Over the past 2 weeks has your itching got better or worse 
compared to the previous month? 
 
Completel
y resolved 
Much 
better, 
but 
still present 
Little 
bit 
better, but 
still present 
Unchanged Getting 
worse 
 
1 
2 
3 
4 
5 
4. Disability 
Rate the impact of your itching on the following activities over 
the last 2 weeks 
x Sleep 
Never 
affects 
sleep 
Occasionall
y 
delays 
falling 
asleep 
Frequently 
delays 
falling 
asleep 
Delays 
falling 
asleep and 
occasionall
y wakes me 
up at night 
Delays 
falling 
asleep and 
frequently 
wakes me 
up at night 
 
1 
2 
3 
4 
5 
x Leisure/ 
social 
x Housewor
k/ Errands 
x Work/ 
Studies 
Never 
affects this 
activity 
Rarely 
affects this 
activity 
Occasionall
y 
affects 
this activity 
Frequently 
affects this 
activity 
Always 
affects this 
activity 
 
1 
2 
3 
4 
5 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
10 
 
5. Distribution 
Mark whether itching has been present in the following parts 
of your body over the last 2 weeks. If a body part is not listed, 
choose the one that is closest anatomically 
Head/ Scalp 
Ƒ 
Top of feet/ Toes 
Ƒ 
Face 
Ƒ 
Soles 
Ƒ 
Chest 
Ƒ 
Palms 
Ƒ 
Abdomen 
Ƒ 
Top of hands/ fingers 
Ƒ 
Back 
Ƒ 
Forearms 
Ƒ 
Buttocks 
Ƒ 
Upper arms 
Ƒ 
Thighs 
Ƒ 
Point of contact w/ clothing 
Ƒ 
Lower Legs 
Ƒ 
Groin 
Ƒ 
 
- Mean change in Skindex-10 (Domain Scores and Total Score) from Baseline to Week 4, Week 
8 and Week 12  
 The Skindex-10 consists of 10 questions (beginning with “During the past week, how 
often have you been bothered by…..”) exploring the impact of itch on 3 domains 
(disease, mood/emotional distress and social functioning) with a 1 week recall period. 
 Each question must be scored on a 7-point scale ranging from 0 (never bothered) to 6 
(always bothered). 
 The domain scores are the sums of the following: disease domain (questions 1 to 3), 
mood/emotional distress domain (questions 4 to 6), and social functioning domain 
(questions 7 to 10). 
 The total score is the sum of the numeric value of each answered question. The total 
score ranges from 0 to 60. 
 Continuous descriptive statistics will be presented for individual questions (Q1- Q10). 
 Domains (1) Disease (Q1- Q3), Domain (2) Mood/ Emotional Distress (Q4 – Q6) and 
Domain (3) Social Functioning (Q-7 – Q10) will be presented using continuous 
descriptive statistics. 
 Mean change in Total Skindex-10 Score will be summarized descriptively from Baseline 
to Week 4, Week 8 and Week 12. 
Table 5  
Skindex-10 Questionnaire 
During the past week, how often have you been bothered by: 
 
0 
(Never 
bothered) 
1 
2 
3 
4 
5 
6 
(Always 
bothered) 
1. Your itching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
2. The 
persistence/ 
reoccurrence of 
your itching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
3. The appearance 
of your skin 
from scratching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
4. Frustration 
about 
your 
itching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
11 
 
5. Being annoyed 
about 
your 
itching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
6. Feeling 
depressed 
about 
your 
itching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
7. Feeling 
embarrassed 
about 
your 
itching 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
8. The effects of 
your itching in 
interactions 
with other 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
9. The effects of 
your itch on 
your desire to 
be with people 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
10. The effect of 
your 
itching 
making hard to 
work 
or 
do 
things 
you 
enjoy 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
Ƒ 
 
- Mean change in EQ-5D-5L (Visual analogue scale [VAS] and Index value) from Baseline to 
Week 4, Week 8 and Week 12 
Note: EQ-5D-5L Index Value (calculated using EQ5D5L algorithm) and VAS (i.e., Your 
Health Today Question) will be analyzed separately. 
EQ-5D-5L Index Value: 
The EQ-5D-5L descriptive system comprises five dimensions (5D) (MOBILITY, SELF-CARE, 
USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), each 
dimension has five response levels (5L): no problems, slight problems, moderate problems, 
severe problems, unable to/extreme problems. The respondent is asked to indicate his/her health 
state by checking the box next to the most appropriate response level for each of the five 
dimensions. 
A unique health state is defined for each subject by combining the response levels from each of 
the five dimensions. EQ-5D-5L health states can thus be summarized using the 5-digit code 
summary number, which reflects how good or bad a health state is according to the preferences 
of the general population of a country/region. 
To compare two or more health states with each other or to understand which dimension has a 
greater impact on health-related quality of life (HRQoL), an index value derived from a set of 
utility values is given to each unique health state. This index value is needed to summarize how 
good or bad each health state is on a scale anchored at 1 (full health) and 0 (a state equivalent 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
12 
 
to dead). Values less than 0 represent health states considered to be or modelled as worse than 
dead.  
The utility values are based on the views and preferences of the general public and numerous 
country-specific value sets were produced by EuroQol Research Organization for EQ-5D-5L. 
The EQ-5D-5L index value for this study will be calculated for patients in United Kingdom 
using English Population Value Set, and for Germany, Hungary and Poland, using German 
population value set, Hungarian population value set, and Polish population value set 
respectively as presented in Table 6.  
An index value thus calculated based upon below mentioned value sets can range anywhere 
between -1 and 1. 
Table 6 
EQ 5D 5L Values sets for United Kingdom (UK), Germany (GR), Hungary (HR) 
and Poland (PL) 
Activity 
Scale 
Score 
UK 
Value 
Set 
GR 
Value 
Set 
HR 
Value 
Set 
PL 
Value 
Set 
Mobility 
I have no problem in 
walking 
1 
0 
0 
0 
0 
 
I have slight problem 
in walking 
2 
0.058 
 
0.026 
0.035 
0.025 
 
I 
have 
moderate 
problem in walking 
3 
0.076 
 
0.042 
0.054 
0.034 
 
I have severe problem 
in walking 
4 
0.207 
 
0.139 
 
0.174 
0.126 
 
I am un able to walk 
5 
0.274 
 
0.224 
 
0.192 
0.314 
 
 
 
 
 
 
 
Self Care 
I have no problem in 
washing or dressing 
myself 
1 
0 
0 
0 
0 
 
I have slight problem 
in washing or dressing 
myself 
2 
0.050 
 
0.050 
 
0.045 
0.031 
 
I 
have 
moderate 
problem in washing or 
dressing myself 
3 
0.080 
 
0.056 
 
0.044 
0.047 
 
I have severe problem 
in washing or dressing 
myself 
4 
0.164 
 
0.169 
 
0.152 
0.111 
 
I am un able to wash or 
dress myself 
5 
0.203 
 
0.260 
 
0.125 
0.264 
 
 
 
 
 
 
 
Usual Activity 
I have no problem in 
performing 
usual 
activities 
1 
0 
0 
0 
0 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
13 
 
 
I have slight problem 
in performing usual 
activities 
2 
0.050 
 
0.036 
 
0.035 
0.023 
 
I 
have 
moderate 
problem in performing 
usual activities 
3 
0.063 
 
0.049 
 
0.050 
0.040 
 
I have severe problem 
in performing usual 
activities 
4 
0.162 
 
0.129 
 
0.132 
0.097 
 
I am un able to 
perform 
usual 
activities 
5 
0.184 
 
0.209 
 
0.059 
0.205 
 
 
 
 
 
 
 
Pain/ Discomfort 
I have no pain and 
discomfort 
1 
0 
0 
0 
0 
 
I have slight pain and 
discomfort 
2 
0.063 
 
0.057 
 
0.043 
0.030 
 
I have moderate pain 
and discomfort 
3 
0.084 
 
0.109 
 
0.030 
0.050 
 
I have severe pain and 
discomfort 
4 
0.276 
 
0.404 
 
0.215 
0.261 
 
I am extreme pain and 
discomfort 
5 
0.335 
 
0.612 
 
0.123 
0.575 
 
 
 
 
 
 
 
Anxiety/ Depression 
I have no anxiety/ 
depression 
1 
0 
0 
0 
0 
 
I have slight anxiety/ 
depression 
2 
0.078 
 
0.030 
 
0.040 
0.018 
 
I 
have 
moderate 
anxiety/ depression 
3 
0.104 
 
0.082 
 
0.053 
0.029 
 
I have severe anxiety/ 
depression 
4 
0.285 
 
0.244 
 
0.168 
0.108 
 
I 
have 
extreme 
anxiety/ depression  
5 
0.289 
 
0.356 
 
0.079 
0.232 
 
 
 
 
 
 
 
 
Overall Utility Value Total (UVT)= Mobility UVT+ Self Care UVT+ Usual Activity UVT+ Pain/ 
Discomfort UVT + Anxiety/ Depression (UVT) 
EQ5D5L Index= 1- Overall UVT (rounded to three decimal points) 
 
EQ-5D-5L VAS Score 
The VAS records the subject’s overall current health on a vertical VAS where the endpoints are 
labelled “(100) The best health you can imagine” and “(0) The worst health you can imagine.” The 
VAS provides a quantitative measure of the subject’s perception of his/her overall health, higher score 
indicating better quality of life. 
 
 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
14 
 
Table 7 
EQ-5D-5L VAS  
Your Health 
today 
On a rate of 0 to 100 how is your health today, 0 being worst 
and 100 being best 
0 - 100 
 
Mean change in EQ-5D-5L Index score and VAS score will be presented descriptively from Baseline 
to Week 4, Week 8 and Week 12. 
 
- Percentage of subjects obtaining a  2-step improvement in Clinician’s Global Assessment (CGA) 
for the following endpoints from Baseline to Week 1, Week 4, Week 8 and Week 12: 
 Skin dryness 
 Skin signs of itch 
 Overall skin appearance (The overall CGA of skin appearance is defined based on the intensity 
of the individual signs skin dryness and skin signs of itch. In case of difference in intensity of 
skin dryness and skin signs of itch then the worst intensity shall prevail in the overall CGA of 
skin appearance) 
- Percentage of subjects obtaining a  2-step improvement in Clinician’s Targeted Assessment 
(CTA) for the following endpoints from Baseline to Week 1, Week 4, Week 8 and Week 12. 
 
Skin dryness 
 
Skin signs of itch 
 
Overall skin appearance (The overall CTA of skin appearance is defined based on the intensity 
of the individual signs skin dryness and skin signs of itch. In case of difference in intensity of 
skin dryness and skin signs of itch then the worst intensity shall prevail in the overall CTA of 
skin appearance) 
Table 8 
CGA/ CTA Score 
CGA/ CTA Score 
Skin Dryness Descriptions 
Skin 
Signs 
of 
Itch 
Description 
Clear 
No skin dryness 
No active signs of itch 
Almost Clear 
Barely perceptible skin dryness Barely recognizable active skin 
signs of itch 
Mild 
Easily perceptible skin dryness Easily recognizable active skin 
signs of itch 
Moderate 
Moderate skin dryness 
Moderate active skin signs of 
itch 
Severe 
Marked skin dryness 
Marked active signs of itch 
 
- The mean change in weekly mean WI-NRS recorded in the subject’s diary will be assessed within 
both arms (MC2-25 cream and MC2-25 vehicle) for change from Baseline to Week 1, Week 4, 
Week 8 and Week 12.  
3.5 
Safety Endpoints 
- Frequencies of treatment-emergent adverse events (TEAEs), treatment-emergent serious AEs 
(TESAEs), treatment-related TEAEs (unlikely related, probably related, and possibly related), 
TEAEs leading to treatment discontinuation or trial withdrawal, and deaths during the trial for MC2-
25 cream compared to MC2-25 vehicle. 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
15 
 
- Mean change in vital signs (heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and body temperature (temp)) from Baseline to Week 4, Week 8 and Week 12 for MC2-25 
cream compared to MC2-25 vehicle. 
Shift in frequencies of clinically significant and not clinically significant vital signs values from 
Baseline to Week 4, Week 8 and Week 12 for MC2-25 cream compared to MC-25 vehicle. 
- Mean change in laboratory assessments (biochemistry and hematology) from Baseline to Week 4 
and Week 12 for MC2-25 cream compared to MC2-25 vehicle. 
Shift in frequencies of normal, abnormal and abnormal clinically significant or not clinically 
significant laboratory values from Baseline to Week 4, Week 8 and Week 12 for MC2-25 cream 
compared to MC-25 vehicle. 
- Shifts in physical examination from Baseline to Week 12 by body area will be displayed.  
Frequencies of normal, abnormal and abnormal clinically significant and abnormal clinically not 
significant values of physical examination from Baseline to Week 12 for MC2-25 cream compared 
to MC-25 vehicle. 
- Shifts in electrocardiograms (ECGs) from Baseline to Week 4 and Week 12 will be displayed.  
Frequencies of normal, abnormal and abnormal clinically significant and abnormal clinically not 
significant values from Baseline to Week 4 and Week 12 for MC2-25 cream compared to MC-25 
vehicle. 
- Percentage of subjects who missed 1 or more dialysis visits during the Double-blind Treatment 
Period as recorded on end of trial visit. Not applicable (NA) category will be presented for subjects 
not on dialysis.  
3.6 
Other Endpoints 
- Skin stripping results will be provided in a separate report. 
4 
Analysis Populations 
The analysis populations are defined as: 
- 
Screened set (SS): all subjects who sign the informed consent form. 
- 
Safety analysis set (SAS): all subjects who are randomized and dispensed trial medication at 
Randomization/Day 0, excluding subjects to whom trial medication is not dispensed or who return 
all the trial medication unused. Subjects will be analyzed according to the actual treatment. 
- 
Full analysis set (FAS): all subjects who are randomized. Subjects will be analyzed according to 
the randomized treatment. 
- 
Modified full analysis set (MFAS): all subjects who are randomized and returned for at least one 
post-baseline scheduled visit with WI-NRS data. Subjects will be analyzed according to the 
randomized treatment. 
- 
Per-protocol set: (PPS): a subset of the MFAS subjects who completed the trial with WI-NRS data 
for Week 12 and are deemed to have no important protocol deviations that could interfere with the 
objectives of the trial. Important deviations of eligibility criteria and other deviations from the 
protocol will be assessed. Important deviations from the protocol may lead to exclusion of a subject 
or data points from the PPS, which could have interfered with the administration of the treatment 
or the evaluation of the treatment effect. A blind data review meeting will be conducted and 
decisions on exclusions of any subjects with important protocol deviations leading to exclusions 
from the per protocol set will be documented before the final trial database is unblinded. 
SAS will be used for all safety analyses. FAS, MFAS, and PPS will be used for efficacy analyses. 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
16 
 
5 
Planned Analyses 
5.1 
Methodological Considerations 
General Conventions: 
- SAS® software (version 9.4 or higher) will be used for all data analyses and tabulations.  
- Data for all investigational centers will be pooled for analysis.  
- Summary tables will report data based upon the protocol scheduled time points. For patients 
who are withdrew early from the study, all efficacy assessments captured at the EoT visit will 
be assigned to the nearest protocol scheduled time point. 
Counts and percentages: Categorical variables will be described by summary tables of 
frequencies (counts and percentages) per treatment group 
Descriptive Statistics: 
Descriptive summaries of continuous data will include number of non-missing values, mean, 
standard deviation (SD), median, minimum, maximum and 1st Quartile (Q1) and 3rd Quartile 
(Q3). Descriptive summaries of categorical variables will include frequencies and percentages. 
Missing values will not contribute to the denominator of the percentages. 
 
Statistical tests: 
Hypothesis Testing- We assume the null hypothesis is that the MC2-25 cream performs less 
than or equal to the MC2-25 vehicle while comparing change from baseline in WI-NRS score 
to Week 12.  
We assume for alternate hypothesis that there is significant difference between the treatments.  
The hypothesis to be tested to address the objective is:  
H0: Change from baseline in mean score of weekly mean of WI-NRS to Week 12 for MC2-25 
cream (į0) <= Change from baseline in mean score of weekly mean of WI-NRS to Week 12 for  
MC2-25 vehicle (į1) 
versus  
H1: Change from baseline mean score of weekly mean of WI-NRS to Week 12 for MC2-25 
cream (į0) > Change from baseline in mean score of weekly mean of WI-NRS to Week 12 for 
MC2-25 vehicle (į1) 
The primary analysis will be conducted on Mean change in weekly mean WI-NRS Score 
recorded in the subject’s diary from Baseline to Week 12 for MC2-25 cream compared to MC2-
25 vehicle and will be analyzed by a mixed model of repeated measures (MMRM). 
Statistical tests will be two-sided with Į = 0.05. Superiority is concluded if a p-value of statistical 
hypothesis testing is below the level and the estimate of treatment difference is in favorable 
direction for MC2-25 cream. 
Due to the phase 2 type of the trial, no adjustment due to multiple testing will be used.  
No interim analyses are planned. SAS® software will be used for all data analyses and 
tabulations. 
Baseline for efficacy and safety summaries is defined as the last observation prior to the first 
application of IMP except for weekly mean WI-NRS which is the average of at least 4 non-
missing WI-NRS values recorded in the subjects’ diaries for the 7 days prior to and including 
the Baseline day. If there are less than 4 observations in the expected 8 days of entries, the 
baseline will be considered missing for weekly mean WI-NRS. 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
17 
 
5.2 
Handling of Dropouts or Missing Data 
5.2.1 Missing Data 
For the primary and secondary efficacy endpoints, the primary estimands using the FAS, MFAS 
and PPS will use a treatment policy strategy for missing data. Missing data will be replaced 
using a multiple imputation (MI) approach. Note, missing data includes dropouts, empty data 
fields after dropout date will be handled as missing data regardless of reason for drop out. MI 
will be performed for all populations separately only if there is a difference in populations. Seed 
numbers for each endpoint will use the randomly generated 4-digit numbers from the table 
below. Other variables that are included in the imputation model will include treatment, site, 
country, visit, and key baseline characteristics such as age, gender, race, CKD stage stratum(1) 
at baseline, and systemic CKD-aP treatment status(2) at baseline. Depending on the pattern of 
missingness, a 2-step process may be employed. If missing data points occur for an intermediate 
visit, they will be imputed first using a Markov Chain Monte Carlo (MCMC) method. As a 
result, a monotone missingness pattern will be obtained for the data to be fully imputed. The 
subsequent imputation will use general regression for continuous variables and logistic 
regression for categorical variables under the assumption data are missing at random to produce 
20 imputed datasets where the remaining missing data are filled in using 20 separate sets of 
values. For the categorical secondary variables, the percentages will be calculated from the 
above imputed data.   
(1) CKD stage stratum at baseline= A. 40% of subjects must be on dialysis (HD or HDF) and 
must be CKD stages 4-5 (CKD stage 4-5 dialysis) B. 20% of subjects must Not be on 
dialysis and must be CKD stages 4-5 (CKD stage 4-5 non-dialysis) C. 20% of subjects 
must Not be on dialysis and must be CKD stage 3 (CKD stage 3) 
(2) Systemic CKD-aP treatment status at baseline will be flagged as “Yes” if prior/concomitant 
medication falls within one of the ATC groups provided in  Section 6.3.2 
 
Table 9  
Population and Random Seed Number 
Population Random Seed Number 
FAS 
6529 
MFAS 
7631 
PPS 
9376 
For each copy of the imputed datasets, both the primary and secondary endpoints involving the 
same endpoint variable will be analyzed in the same way as described in the primary and 
secondary analyses in Sections 5.5.1 and 5.5.2, respectively. Results from the copies of the 
imputed datasets will be synthesized using SAS® Proc MIANALYZE. 
Using the FAS for the primary endpoint analyses, a sensitivity analysis will be performed using 
last observation carried forward (LOCF; treatment policy). If a subject is given prohibited 
therapy, all missing data and data for visits after the start of prohibited therapy will use the MI 
approach described above in another analysis (hypothetical strategy).  
If deaths occur, further estimands may be defined following a composite endpoint strategy. 
There will be no imputation of missing data for the PPS which will use the data as observed 
following a treatment policy strategy. There will be no imputation of missing data for safety 
endpoints. 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
18 
 
5.2.2 Missing Data Handling- A While-on-Treatment Strategy 
If, on the week of interest, for both primary and secondary endpoints, data is missing for more 
than 5 subjects due to permanent premature treatment discontinuation, then imputation will be 
performed using the missing data imputation approach and by disregarding any available data 
for those subjects. 
5.2.3 Analysis Windows 
As subjects do not always adhere to the protocol visit schedule, the following rules are applied 
to assign actual visits to analysis visits. Listed below are the visit windows and the target days 
for each visit. The reference day is Baseline, Study day 1. If a subject has 2 or more actual visits 
in 1 visit window, the visit closest to the target day will be used as the protocol visit for that 
visit window. The other additional visit(s) will not be used in the summaries or analyses, but 
they can be used for determination of clinically important endpoints. If 2 actual visits are 
equidistant from the target day within a visit window, the later visit is used. 
Table 10 represents the analysis windows assigned for efficacy and safety analysis and the 
corresponding range of treatment days (window) during which data for a particular nominal 
visit will be collected. The analysis windows will be calculated from the first application of 
study product. These are analysis windows that contain, but are not same as, the actual visit 
windows.  
For assessments that are not planned on Week 1, the visit window  for such assessments will be 
starting at Week 4. 
Table 10 
Study Period, Visit and Target Day 
Study Week/ Period 
Study Visit 
Target Day 
Window 
Screening 
Visit 1 (V1) 
-28 to -1 
 
Baseline/ Week 0 (on site) 
Visit 2 (V2) 
1 
1 
Week 1 (on site) 
Visit 3 (V3) 
8 (±1) 
2-19 
Week 4 (on site) 
Visit 5 (V5) 
29 (±4) 
20-43 
Week 8 (on site) 
Visit 7 (V7) 
57 (±4) 
44-71 
Week 12 (on site/EoT) 
Visit 9 (V9) 
85 (±4) 
72-92 
Week 14 (FU) 
Visit 10 (V10) 
±2 Weeks after EoT 
 
For the hypothetical strategy, subjects given prohibited therapies will have WI-NRS data set to 
missing for visits after the start of the prohibited therapies and then missing data will be 
estimated using MIs. Subjects with an ET visit will be excluded from the PPS analyses. Safety 
data collected during an ET visit will remain at the Week 12/EoT visit. 
Note: As per the CDISC, baseline is defined as Day 1 and not as Day 0. Therefore, there is a 
difference of one day between study day as defined in protocol and target day (Table 10). 
5.2.4 COVID-19 Impacted Visits 
Since the primary and secondary efficacy endpoints are derived from the subjects’ diaries and 
summaries of other efficacy endpoints and safety endpoints are as observed, there will be no 
adjustments made for coronavirus disease of 2019 (COVID-19) impacted visits.  
5.3 
Demographics and Background Characteristics 
Subject demographics and background characteristics will be summarized for the FAS, MFAS 
(if it differs from the FAS) and SAS using descriptive statistics by treatment group and overall. 
Demographics will include age, age-group (<=65, 66–79, and 80 and above years) sex, race, 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
19 
 
ethnicity, 
weight, 
height, 
body 
mass 
index 
(BMI). 
BMI 
is 
derived 
using: 
BMI (kg/m2) = weight (kg) / [height (m)]2. Background characteristics include CKD stage and 
duration, whether subjects are on dialysis or not and time in months (month will be calculated 
as number of days divided by 30) since initiation of dialysis. Number of times subject has 
dialysis in a week and use of anti-CKD-ap medication (see Section 6.3.2) at baseline will also 
be reported.  Baseline weekly mean WI-NRS, time in months since start of CKD-aP, selected 
laboratory parameters (Serum Urea, Serum Creatinine) and, baseline CGA and CTA. 
Medical and surgical history will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA) version 24.1 and will be summarized using descriptive statistics by 
system organ class (SOC), preferred term (PT) and by treatment group and overall. If a subject 
has more than one medical or surgical history event in an SOC or PT, the subject will be counted 
once within the term. 
Subject demographics, background characteristics, and medical history will be listed by country, 
site and subject. 
5.4 
Subject Accountability 
Subjects screened, reason for screen failure, subjects randomized, subject disposition, reason for 
withdrawal from trial, reason for discontinuation of treatment, and analysis populations will be 
summarized using descriptive statistics for the SS by treatment group and overall. Subjects 
screened, subject disposition and populations status will be summarized using descriptive 
statistics for the SS by site and by treatment group and overall. Major protocol deviations will 
be summarized using descriptive statistics using the SAS for all sites and by site and by 
treatment group and overall. Screen failures, subject disposition including reason for 
discontinuation, and protocol deviations will be listed by country, site and subject. 
5.5 
Efficacy Analyses 
All efficacy summaries and analyses will be provided for the FAS, MFAS and PPS (if MFAS 
and PPS are different than FAS)  
5.5.1 Primary Efficacy Analyses 
The primary endpoint will be analyzed using a mixed model of repeated measures (MMRM) 
with baseline weekly mean WI-NRS as a covariate and treatment, CKD stage stratum at baseline, 
systemic CKP-aP treatment status at baseline and visit as fixed factors and subject as a random 
factor with a 2-sided Į = 0.05. An unstructured variance/covariance structure will be used. Least 
squares (LS) means and standard errors (SE) for each treatment group will be displayed along 
with the difference in LS means between active and vehicle with the corresponding SE, 95% 
confidence interval (CI) and p-value. 
Descriptive summaries and listings by subject and visit will be provided. 
5.5.1.1 
Subgroup Analysis 
Supportive subgroup analyses will be conducted following same model as primary efficacy 
analyses also in addition to by CKD stage strata  and by country on the FAS.  
Subject’s dialysis information will be listed by subject, country, and site. 
5.5.2 Secondary Efficacy Analyses 
The key secondary and other secondary endpoints will be analyzed using a generalized 
estimating equations model with baseline weekly mean WI-NRS as a covariate and treatment, 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
20 
 
CKD stage stratum at baseline, systemic CKP-aP treatment status at baseline and visit as fixed 
factors and subject as a random factor with a 2-sided Į = 0.05. An exchangeable covariance 
structure will be used. Estimates and SE for each treatment group will be displayed along with 
the difference in estimates between active and vehicle with the corresponding SE, 95% CI and 
p-value. 
Descriptive summaries and listings by subject and visit will be provided. 
5.5.3 Other Efficacy Analyses 
Descriptive summaries will be provided for all other efficacy endpoints by visit and treatment 
group. They will also be listed by subject and visit.  
The mean change in weekly mean WI-NRS from baseline to Week 1, 4, and 8, respectively, 
will be analyzed like described for the primary efficacy analysis in Section 5.5.1.  
The mean change in weekly mean WI-NRS will be assessed within treatment for both arms 
(MC2-25 cream and MC2-25 vehicle) for change from baseline for all visits i.e., Week 1, 4, 8 
and 12 using a paired T-test.  
5.6 
Other Safety Variables and Analyses 
Safety endpoints will be summarized using the SAS by treatment group and overall and will 
use descriptive statistics only. 
5.6.1 Product Compliance 
Subjects enrolled in the trial are required to apply the IMP twice daily during the 12 week 
double-blind treatment period starting on the day of randomization (Baseline) and ending on 
the Week 12 visit date (End of Treatment). The total number of IMP applications and the 
number of missed applications during this period is recorded in the Treatment Application 
Record on a daily basis and entered in the eCRF.   
 
The applications compliance rate for each subject is defined as: 
Compliance = (Actual number of applications in treatment period / Number of expected 
applications in treatment period) * 100. 
Where; 
Actual number of applications in treatment period =  Total number of applications applied 
during the course of the trial as reported in the eCRF 
Number of expected applications in treatment period = Total number of days from baseline 
visit (randomization) till Week 12 (EoT) or early withdrawal X 2 (Twice daily application) – 2 
Duration of treatment period = Total number of days from baseline visit (randomization) till 
Week 12 (EoT) or early withdrawal  
Compliance will be summarized in following categories; less than 80%, 80 to 100% 
and >100%  (in cases where subject used the medication more than prescribed times a day) and 
average compliance in each treatment arm. Accumulated subject listings will also be presented 
for compliance. 
100% compliance means the subject applied IMP twice daily as prescribed for total number of 
days in the trial and there were no missed applications between first and last application.  


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
21 
 
Descriptive statistics will be used to summarize product compliance for the SAS. Subject listing 
for compliance will be presented by 4-week periods (Baseline to < Week 4,  Week 4 to < 
Week 8, and  Week 8 and for overall trial period. 
5.6.2 Drug Accountability and Extent of Exposure: 
As a part of drug/product accountability, the amount of trial product dispensed and returned 
(used and unused) will be kept during the trial at each visit and at completion of the trial. Each 
dispensed kit consists of 5 tubes with each tube having a weight of 74.8 grams (tube with cream 
and label). 
Subjects will return all used and unused tubes at Week 4, 8 and 12 visits and all returned tubes 
which have broken seals will be weighed to determine the residual amount of the IMP. The 
following averages will be calculated for all subjects as well as for subjects returning at least 
80% of the IMP dispensed during the trial: 
 
1. Weight of IMP used during the  trial per subject  
2. Weight of IMP used during the trial per subject per number of weeks on treatment 
3. Weight of IMP used during the trial per subject per % BSA at Baseline 
4. Weight of IMP used during the trial per subject per number of weeks on treatment per % 
BSA at Baseline 
Weight of IMP used during the trial per subject = (74.8 grams times the total number of tubes 
returned at Week 4, Week 8, and Week 12 visits) + (50 grams times the total number of 
dispensed tubes not returned) – (the sum of the weight of all tubes returned at Week 4, Week 8, 
and Week 12 visits). Notes: The minimum weight of IMP used is 0 grams. Number of weeks 
on treatment is defined as the period from first to last application expressed in weeks. 
Drug accountability information will be summarized for SAS and listed by subject.  
5.6.3 Prior and Concomitant Therapies/ Medications 
Prior Therapies/ Medications: 
Prior Therapies/Medications include any therapy or medication with start date prior to the start 
of IMP application. They will be classified according to the World Health Organization Drug 
Dictionary (WHO-DD; version March 2022 Q) as prior medication.  
Concomitant Therapies/ Medications: 
Concomitant therapies/ medication will include therapies/ medications starting before or after 
the start of IMP application and continuing after the start of IMP application. They will be 
classified according to the WHO-DD; version March 2022 Q. 
 
Descriptive summaries will be by WHO-DD Anatomical Therapeutic Chemical (ATC) level 2 
and ATC level 4. There will be separate summaries for all prior therapies/ medications, prior 
therapies/ medications that were ongoing at baseline, and concomitant therapies/ medications. 
Prior and concomitant therapies/ medications will be listed by subject. 
5.6.4 Adverse Events 
Adverse events (AE) will be coded using MedDRA version 24.1 terminology. Treatment-
emergent adverse events (TEAEs) related TEAEs (unlikely related, possibly related, and 
probably related), non-serious TEAEs, serious TEAEs (TESAEs), related TESAEs, TEAEs 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
22 
 
leading to treatment discontinuation or trial withdrawal, and deaths will be summarized for the 
overall incidence of at least one event, incidence by SOC and incidence by SOC and PT.  
By definition, TEAE is an AE that began after the start of trial medication treatment.  TESAE’s 
are any TEAE’s that are reported as serious in the eCRF. 
Each subject will contribute only once to each of the incidence rates, regardless of the number 
of occurrences (events) the subject experiences. The number of occurrences for each SOC and 
PT will also be displayed. 
TEAEs will also be descriptively summarized by severity (mild, moderate or severe) and by 
relationship to IMP [not related or related (unlikely related, possibly related and probably 
related)]. In summaries of severity and relationship, subjects who report more than one event 
mapped to the same SOC or PT will be counted only once under the strongest severity and 
relationship, accordingly. 
An AE is treatment-emergent if its date of onset in on or after the first application date of IMP. 
An AE is related if relationship to IMP is assessed as unlikely related, probably related, or 
possibly related. 
TEAEs, TESAEs, TEAEs leading to treatment discontinuation or study withdrawal and deaths 
will be listed by subject. 
5.6.5 Other Safety Endpoints 
Other safety endpoints include hematology and biochemistry laboratory values, vital signs, 
physical examination and ECG findings.  
Physical examination and ECG findings will be summarized as categorical variables (Normal, 
Abnormal not clinically significant, Abnormal clinically significant) by visit.  
Hematology and biochemistry laboratory values and vital signs (heart rate, systolic blood 
pressure, diastolic blood pressure, temperature, height and weight) will be summarized as 
continuous variables by visit.  
The percentage of subjects who missed 1 or more dialysis visits during the Double-blind 
Treatment Period will also be summarized. 
Each of the above parameters will be listed by subject and, if applicable, visit. 
6 
Appendices 
6.1 
Handling of Missing or Incomplete Dates for Adverse Events , Prior and Concomitant 
Medications 
Adverse Events  
Handling of partial dates is only considered for the start date. An adverse event with a partial 
start date is considered treatment emergent if:  
- only the day is missing and the start month/year is the same or after the month/year of the 
first application 
- the day and month are missing and the start year is the same or greater than the year of the 
first application date  
- the start date is completely missing  
Prior and Concomitant Therapies 
A medication or therapy is considered prior medication or therapy if: 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
23 
 
- only the day is missing and the start month/year is prior to the month/year of the treatment 
start date. 
- the day and month are missing and the start year is the same or before than the year of the 
first dose date 
- the start date is completely missing or the medication is not-ongoing. 
A medication or therapy is considered concomitant medication if: 
- only the day is missing and the stop month/year is the same or after the month/year of the 
first dose 
- the day and month are missing and the stop year is the same or greater than the year of the 
first dose date 
- the stop date is completely missing or the medication is ongoing. 
A medication is considered both prior and concomitant if the start date is before the treatment start 
date and the stop date is after treatment start date or if the medication is ongoing.  
6.2 
Changes in analyses from protocol: 
Section 
Detail 
3.3 
Percentage of subjects obtaining a complete response in weekly WI-NRS recorded 
in the subjects’ diaries from Baseline to Week 1, Week 4, Week 8 and Week 12.  
As per protocol version 2.0 dated 24 Aug 2022, complete response is defined as 
scored equal to 0 or 1 in >80% of the non-missing WI-NRS values recorded in 
subjects diaries 7 days prior to and including the scheduled in clinic visits. 
Additional tables using the threshold value of 70% will be developed. This is 
justified by published paper as given below: 
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in 
Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus and 
Not on Dialysis 
Efficacy Assessment Phase (Treatment Period 1): Proportion of subjects who are 
"complete itch responders" defined as subjects with ı 70% of the non-missing 
24-hour WI-NRS scores equal to 0 or 1 at Week 12 of Treatment Period 1. [ Time 
Frame: Week 12 of Treatment Period 1 ] 
Intensity of itch will be measured using an NRS used to indicate the intensity of 
the worst itching over the past 24 hours using a 0 to 10 numeric rating scale, where 
"0" represents "no itching" and "10" represents "worst itching imaginable". 
https://clinicaltrials.gov/ct2/show/NCT05356403?term=cr845&draw=3&rank=20 
3.6 
Deleted analysis as described in Section 4.2 Protocol, Other endpoints 
-Changes in biomarkers in skin punch biopsy samples from Baseline to Week 12 
for MC2-25 cream compared to MC2-25 vehicle. 
 
 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
24 
 
6.3 
Reference Materials 
6.3.1 EQ-5D-5L Index Value 
The EQ-5D-5L descriptive system comprises five dimensions (5D). The respondent is asked to 
indicate his/her health state by checking the box next to the most appropriate response level for 
each of the five dimensions. 
A unique health state is defined for each subject by combining one level from each of the five 
dimensions. A total of 3125 possible unique health states is defined in this way. Each state is 
referred to by a 5-digit code.  
For example, working clockwise from the top of the diagram, state 12345 indicates no problems 
with mobility, slight problems with washing or dressing, moderate problems with doing usual 
activities, severe pain or discomfort and extreme anxiety or depression, while state 11111 
indicates no problems on any of the five dimensions and 55555 indicates extreme problems at 
each dimension. 
 
EQ-5D-5LUserGuide Basic information on how to use the EQ-5D-5L instrument Version3.0 
https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/ 
Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary 
DOI link: https://doi.org/10.1016/j.jval.2020.03.019 
Published Print: 2020-09 
Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and 
Eastern Europe 
Crossref DOI link: https://doi.org/10.1007/s40273-019-00811-7 
Published Print: 2019-09 
Value Sets for EQ-5D-5L- A Compendium, Comparative Review & User Guide 
https://doi.org/10.1007/978-3-030-89289-0 


MC2 Therapeutics 
Protocol No- MC2-25-C1 V3.0 
SAP Final V1.0 
25 
 
Valuing healthဨrelated quality of life: An EQဨ5Dဨ5L value set for England 
DOI: 10.1002/hec.3564 
German Value Set for the EQ-5D-5L 
https://doi.org/10.1007/s40273-018-0615-8 
 
6.3.2 Systemic treatment CKD-aP can be identified via ATC code Level 3 or 4: 
R06A Antihistamines for systemic use 
R06AA Aminoalkyl ethers 
R06AB Substituted alkylamines 
R06AC Substituted ethylene diamines 
R06AD Phenothiazine derivatives 
R06AE Piperazine derivatives 
R06AK Combinations of antihistamines 
R06AX Other antihistamines for systemic use 
H02A Corticosteroids for systemic use, plain 
H02B Corticosteroids for systemic use, combinations 
For some of them only Level 4 could be the most specific: 
N02BF Gabapentinoids 
N02BG Other analgesics and antipyretics